ANAM -17-21  
Final ( v5.0)/13 Jul  2022   Clinical Study Protocol  Helsinn Healthcare SA  
  
 
Page 1 of 110 
CONFIDENTIAL   
A PHASE 3, RANDOMIZED, DOUBLE -BLIND, PLACEBO-
CONTROLLED, MULTICENTER STUDY TO EVALUATE THE 
EFFICACY AND SAFETY OF ANAMORELIN HCL FOR THE 
TREATMENT OF MALIGNANCY ASSOCIATED WEIGHT LOSS AND 
ANOREXIA IN ADULT PATIENTS WITH ADVANCED NON -SMALL 
CELL LUNG CANCER (NSCLC)  
 
Study Number  ANAM -17-21 
Protocol Version  Final ( v5.0) 
Protocol Date  
EudraCT No.  13 Jul  2022  
2018 -[ZIP_CODE] 7-40 
Sponsor  Helsinn Healthcare SA  
Via Pi[INVESTIGATOR_178216] 9  
6912 Lugano, Switzerland  
Phone: [PHONE_3847] 21  
Fax: [PHONE_3847] 22  
 
Clinical CRO  PSI CRO AG  
Baarerstrasse 113a 
6300 Zug, Switzerland  
CRO for Statistics and Data Management  
 
 
  
Business & Decision Life Sciences  
141 rue Saint Lambert  
1200 Brussels, Belgium 
 
  
 
Confidential Information  
The information contained in this document is confidential. Acceptance of this document constitutes agreement by [CONTACT_1955][INVESTIGATOR_178217] e xcept that this 
document may be disclosed to appropriate Institutional Review Boards and Ethics Committees or duly authorized representatives  of a 
Regulatory Authority under the condition that they are requested to keep it confidential.  
The clinical trial will be conducted, and essential study documentation archived, in compliance with this protocol, applicable SOP’s 
and standards, which incorporate the requirements of the EU Clinical Trials Directive 2001/20/EC  or European Regulation 536/2014, 
whichever applies,  FDA Guidance on Conduct of Clinical Trials of Medical products and ICH Guideline for Good Clinical Practice. 
  
ANAM -17-21  
Final ( v5.0)/13 Jul  2022   Clinical Study Protocol  Helsinn Healthcare SA  
  
 
Page 2 of 110 
CONFIDENTIAL   
Signature [CONTACT_3490], Helsinn Healthcare SA  
 
Medical & Scientific Expert , Clinical Research & Development: 
 ________________________________________ __________
(Signature)      (Date)  
 
 
Clinical Operations Lead, Clinical Research & Development
 
_______________________________________ _______
(Signature)      (Date)  
 
 Lead Statistician, Clinical Research and Development:
 ________________________________________ __
(Signature)      (D
 
 
Drug Safety Manager, Regulatory Affairs & Drug Safety :
 ________________________________________ ____
(Signature)      (Date
 
 
Medical Writer , Clinical Research & Development : 
 ________________________________________ 
(Signature)      
 
  

ANAM -17-21  
Final ( v5.0)/13 Jul  2022   Clinical Study Protocol  Helsinn Healthcare SA  
  
 
Page 4 of 110 
CONFIDENTIAL   
Signature [CONTACT_3490], Study Site Investigator  
Study Title  
A phase 3, randomized, double -blind, placebo- controlled, multicenter study to evaluate 
the efficacy and safety of anamorelin HCl for the treatment of malignancy associated 
weight loss and anorexia in adult patients with advanced non -small cell lung cancer 
(NSCLC)  
 
Study Number  ANAM -17-[ADDRESS_209360] and oversee sub- investigator(s) and other relevant staff membe rs under my control and will 
ensure that all trial staff members have access to copi[INVESTIGATOR_178218] (e.g., Investigator’s Brochure), ICH GCP guidelines, local regulations and the Declaration of Helsinki to enable them to work in accordance with the provisions of these documents.  
I will use only the informed consent form approved by [CONTACT_1636]/Independent Ethics Committee (IRB/IEC) and will fulfil all responsibilities for submitting pertinent information to the IRB/IEC responsible for this trial.  
I agree that Helsinn or its representatives or Health Authorities shall have access to any 
source documents from which (e)CRF information may have been generated.  
I agree that all documentation supplied to me by [CONTACT_178251](s) concerning this 
trial will be kept in the strictest confidence.  
  
________________________________________ __________________ 
(Signature) (Date)  
Printed Name:   
[CONTACT_16277]:   
ANAM -17-21  
Final ( v5.0)/[ADDRESS_209361] OF ABBREVIATIONS  .........................................................................................28  
1 INTRODUCTION AND RATIONALE  .................................................................31  
1.1 Background Information ....................................................................................31  
1.2 Anamorelin: preclinical and clinical data ..........................................................32  
1.2.1  Preclinical Data  ..............................................................................................32  
1.2.2  Phase 1 Clinical Data .....................................................................................33  
1.3 Other Clinical Data  ..............................................................................................33  
1.4 Study Rationale ....................................................................................................34  
1.4.1  Rationale for Study Population ....................................................................34  
1.4.2  Rationale for Study Protocol and Design.....................................................35  
1.4.3  Rationale for Selected Dose Range ...............................................................35  
1.5 Rationale for protocol amendment.....................................................................35  
2 STUDY OBJECTIVES  ............................................................................................36  
2.1 Primary Objective  ................................................................................................36  
2.1.1  Estimand .........................................................................................................36  
2.2 Secondary Objectives ...........................................................................................37  
3 STUDY ENDPOINTS  ..............................................................................................38  
3.1 Efficacy Endpoints  ...............................................................................................38  
3.1.1  Primary Efficacy Endpoint ...........................................................................38  
3.1.2  Secondary Efficacy Endpoints  ......................................................................38  
3.1.3  Exploratory Efficacy Endpoints ...................................................................38  
3.2 Safety Assessments ...............................................................................................39  
4 STUDY PLAN ...........................................................................................................40  
4.1 Study Design  .........................................................................................................40  
4.2 Study Duration  .....................................................................................................40  
4.3 Study population  ..................................................................................................40  
4.3.1  Number o f Subjects ........................................................................................40  
4.3.2  Inclusion Criteria  ...........................................................................................40  
4.3.3  Exclusion Criteria  ..........................................................................................42  
5 STUDY DRUG MANAGEMENT  ...........................................................................44  
5.1 Description of Study Treatments  ........................................................................44  
5.2 Treatment Groups  ...............................................................................................44  
5.3 Dose and Administration .....................................................................................44  
5.4 Packaging, Labelling and Shipment  ...................................................................44  
5.5 Storage ..................................................................................................................44  
5.6 Drug Depots  ..........................................................................................................45  
5.7 Accountability  ......................................................................................................45  
5.8 Administration of Study Treatment ...................................................................45  
5.9 Blinding  .................................................................................................................46  
ANAM -17-21  
Final ( v5.0)/[ADDRESS_209362] ..................................................................................................50  
6.1 Study Procedures by [CONTACT_24326]  ........................................................................50  
6.1.1  Visit 1 (Screening, Day -7 to Day -1) ............................................................50  
6.1.2  Visit 2 (Randomization/Treatment Period, Day 1): Week 1 ......................51  
6.1.3  Visit 3 (Day 22+3): Week 3 ............................................................................52  
6.1.4  Visit 4 (Day 43+3days): Week 6 ....................................................................53  
6.1.5  Visit 5 (Day 64+3 days): Week 9 ...................................................................54  
6.1.6  Visit 6 (Day 85+3): Week 12 ..........................................................................55  
6.1.7  Visit 7 (Day 106+3): Week 15 ........................................................................56  
6.1.8  Visit 8 (Day 127+3) – Week 18  ......................................................................57  
6.1.9  Visit 9 (Day 148+3): Week 21 ........................................................................58  
6.1.10  Visit 10 (Day 169+3): Week 24 ......................................................................59  
6.1.11  Visit 11 (Follow- up visit): Week 26  ..............................................................60  
6.2 Definition of study Completion  ...........................................................................60  
6.3 Premature Discontinuation of Study Drug  ........................................................60  
6.4 Diet and Lifestyle  .................................................................................................61  
7 METHODS OF ASSESSMENT ..............................................................................62  
7.1 Efficacy Assessments  ...........................................................................................62  
7.1.1  Assessment of Body Weight ..........................................................................62  
7.1.2  Assessment of anorexia symptoms and other patient reported 
outcomes ..........................................................................................................63  
7.1.3  Patient Reported Outcome ............................................................................63  
7.2 Safety Assessments ...............................................................................................65  
7.2.1  Demographic/Medical History  ......................................................................[ADDRESS_209363] scan for Tumor Assessment  ....................................................................67  
8 ADVERSE EVENTS  ................................................................................................68  
8.1 Definition of Adverse Events ...............................................................................68  
8.1.1  Classification of Adverse Events...................................................................69  
8.1.2  Reporting Adverse Events  .............................................................................71  
ANAM -17-21  
Final ( v5.0)/13 Jul  2022   Clinical Study Protocol  Helsinn Healthcare SA  
  
 
Page 7 of 110 
CONFIDENTIAL   
8.1.3  Reporting Serious Adverse Events  ...............................................................72  
8.1.4  Pregnancy Report  ..........................................................................................73  
9 STATISTICS  .............................................................................................................74  
9.1 Stratification factors  ............................................................................................74  
9.2 Sample Size Determination  .................................................................................74  
9.3 Definition of Study Populations for Analysis (Analysis Set) ............................75  
9.4 Statistical Analysis  ...............................................................................................75  
9.4.1  Missing Data ...................................................................................................75  
9.4.2  Multiplicity  .....................................................................................................76  
9.4.3  Subgroups  .......................................................................................................77  
9.4.4  Analysis of Demographics, Baseline Variables and Disease 
Characteristics ................................................................................................77  
9.4.5  Efficacy Analysis ............................................................................................77  
9.4.6  Safety Analysis ...............................................................................................82  
9.4.7  Determination of the responder threshold in the 5 -item Anorexia 
Symptom Subscale  .........................................................................................83  
9.4.8  Determination of the clinically meaningful responder threshold in weight change .................................................................................................84
 
9.5 Interim Analysis  ...................................................................................................85  
10 ETHICAL AND REGULATORY ASPECTS ........................................................86  
10.1  Ethical Considerations.........................................................................................86  
10.1.1  Laws and Regulations ....................................................................................86  
10.1.2  Patient’s information sheet and informed consent form  ............................86  
10.1.3  Protocol amendments  ....................................................................................86  
10.1.4  Protocol deviations .........................................................................................87  
10.1.5  Data collection ................................................................................................87  
10.1.6  Monitoring and Quality Assurance  ..............................................................88  
10.1.7  Study Documentation and Records retention .............................................88  
10.1.8  Confidentiality  ................................................................................................89  
10.1.9  Publication policy  ...........................................................................................89  
10.1.10  Insurance  ........................................................................................................90  
11 REFERENCES  .........................................................................................................91  
12 APPENDICES  ...........................................................................................................95  
APPENDIX 1:  EASTERN COOPERATIVE ONCOLOGY GROUP 
PERFORMANCE SCALE  ......................................................................................96  
APPENDIX 2:  BODY WEIGHT MEASUREMENTS -STUDY SPECIFIC 
PROCEDURES  .........................................................................................................97  
APPENDIX 3:  CYP3A4 INHIBITORS AND INDUCERS  ......................................98  
APPENDIX 4:  FACIT MEASUREMENTS  ..............................................................99  
APPENDIX 5:  SCORING GUIDELINES  ...............................................................104  
APPENDIX 6:  PATIENT GLOBAL IMPRESSION OF SEVERITY 
(PGIS) AND PATIENT GLOBAL IMPRESSION OF CHANGE (PGIC)  .......107  
APPENDIX 7:  HUNGER ASSESSMENT SCALE  ................................................109  
ANAM -17-21  
Final ( v5.0)/13 Jul  2022   Clinical Study Protocol  Helsinn Healthcare SA  
  
 
Page 8 of 110 
CONFIDENTIAL   
APPENDIX 8:  NEW YORK HEART ASSOCIATION (NYHA) 
CLASSIFICATION  ................................................................................................110  
 
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 9 of 110 
CONFIDENTIAL   
 
GENERAL INFORMATION 
Sponsor  Helsinn Healthcare SA  
Via Pi[INVESTIGATOR_178216] 9  
6912 Lugano, Switzerland 
Phone: [PHONE_3847] 21 Fax: [PHONE_3847] 22
 
Clinical CRO   
   CRO for Statistics and Data Management
 PSI CRO AG  
Baarerstrasse 113a  
6300 Zug, Switzerland  Business & Decision Life Sciences SA  
[ADDRESS_209364] for Serious
Adverse Events (SAEs)   
  
  
Drug Safety Officer  Helsinn Healthcare SA:  
 
  
CRO:  
 
 
 
 
  
Sponsor Medical Expert  [INVESTIGATOR_178326]:  
 
 

ANAM -17-21  
Final (v5.0 )/[ADDRESS_209365] Manager Helsinn Healthcare SA : 
 
 
  
CRO:  
 
 
 
 
 
Statistics  Helsinn Healthcare SA:  
 
 
CRO:  
 
 
 
  
Data Management Helsinn Healthcare SA:  
 
 
  
CRO:  
  
 
 
 
  

ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 11 of 110 
CONFIDENTIAL   
 
Quality Assurance Helsinn Healthcare SA:  
 
 
CRO : 
 
 
 
 
Clinical Drug Supplies  
Packaging and Labeling 
 Catalent [LOCATION_013] Schorndorf GmbH  
Steinbeisstr. 1-2 
D-[ZIP_CODE] Schorndorf, [LOCATION_013] 
Central laboratory Corporate HQ:  
Eurofins Central Laboratory Bergschot 71 4817 PA Breda, The Netherlands 
US HQ:  
Eurofins Central Laboratory 
[ADDRESS_209366] Philadephia PA [ZIP_CODE], [LOCATION_003] 
 
  

ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 12 of 110 
CONFIDENTIAL   
 
STUDY SYNOPSIS 
Study Title  A Phase 3 Randomized, Double -Blind, Placebo-Controlled, 
Multicenter Study to Evaluate the Efficacy and Safety of 
Anamorelin HCl for the Treatment of Malignancy 
Associated Weight Loss and Anorexia in adult patients with 
Advanced Non- Small Cell Lung Cancer (NSCLC)  
Study Number ANAM -17-21 
Sponsor Helsinn Healthcare SA, Via Pi[INVESTIGATOR_178216] 9, 6912 Lugano, Switzerland  
Countries and Sites Multi- center international study, with sites including, but not 
limited to, North America , Australia  and Europe 
Clinical Phase  Phase 3  
Indication Treatment of malignancy associated weight loss or anorexia in patients with NSCLC  
Study Design Multicenter, randomized, double -blind, parallel -group, 
placebo -controlled study to evaluate the efficacy and safety 
of anamorelin HCl. Approximately 316 patients with 
advanced NSCLC with cachexia will be randomized 1:1 to anamorelin HCl 100 mg or placebo, taken orally once daily (QD) for a total of [ADDRESS_209367] meal of 
the day . 
Objectives  Primary : To demonstrate superiority of anamorelin HCl vs 
placebo on the gain in body weight and improvement in 
anorexia symptoms.   
Secondary : To evaluate the safety and tolerability  of 
anamorelin HCl , and to further evaluate anamorelin efficacy 
profile . 
Treatment Groups Group 1 / Test group – 100 mg anamorelin HCl 
(administered as 100 mg tablets in the fasted condition) 
Group 2 / Control group – Placebo (administered as 
matching placebo tablets in the fasted condition) 
Drug Administration  Patients will take 1 tablet on Day 1 (if a fasting state is not possible on Day 1, the patient will start study drug on Day 2) and daily thereafter until Visit 10 (Week 24). Patients wi ll 
be supplied with study drug and re -supplied at Visit 3 (Week 
3), Visit 4 (Week 6), Visit 5 (Week 9), Visit 6 (Week 12), 
Visit 7 (Week 15), Visit 8 (Week 18), and Visit 9 (Week 
21). Tablets of study drug will be taken orally in mornings 
ANAM -17-21  
Final (v5.0 )/[ADDRESS_209368]. Water is 
permitted prior to and with study drug. 
Study Duration Total of 24 weeks double- blind treatment with anamorelin or 
placebo. A follow -up telephone visit is scheduled at Week 
26. 
Number of Patients  A total of 316 patients with advanced NSCLC with cachexia 
will be randomized 1:1 to anamorelin HCl 100 mg or 
placebo (158 patients per treatment arm).  
Target Study 
Population Advanced NSCLC adult patients with body mass index < 20 
kg/m2 with involuntary weight loss of >2% within 6 months 
prior to screening and anorexia 
Inclusion Criteria  1. Signed written informed consent. 
2. Female or male ≥18 years of age . 
3. Documented histologic or cytologic diagnosis of 
American Joint Committee on Cancer (AJCC) Stage III 
or IV NSCLC. Stage III patient must have unresectable 
disease. 
4. Body mass index < 20 kg/m2 with involuntary weight 
loss of >2% within 6 months prior to screening. 
5. Ongoing problems with appetite/eating associated with the underlying cancer, as determined by [CONTACT_178252] 
≤ 17 points on the 5-item Anorexia Symptom Scale and 
≤ [ADDRESS_209369] A/CS . 
6. Patient receiving or not receiving systemic anti -cancer 
treatment at the time of screening are eligible to 
participate. Systemic anti- cancer treatment includes first, 
second, third treatment line with chemotherapy/radiation therapy, immunotherapy or targeted therapy.   
Patient not receiving systemic anti- cancer treatment is 
eligible if: 
a. Not planning to receive anti- cancer treatment and/or 
at least [ADDRESS_209370] be elapsed from the completion 
of prior treatment at the day of screening, in case underwent previous cycle, 
OR 
b. Planning to receive anti- cancer treatment within 14 
days from randomization and/or at least [ADDRESS_209371] be elapsed from the completion of prior treatment at the day of screening, in case underwent previous cycle, 
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 14 of 110 
CONFIDENTIAL   
 
OR 
c. Patient on palliative care treatment . 
7. ECOG performance status 0,  1 or 2 at screening (see 
APPENDIX 1 ). 
8. AST (SGOT) and ALT (SGPT) ≤ [ADDRESS_209372] or if hepatic 
metastases are present ≤ [ADDRESS_209373] . 
9. Adequate renal function, defined as creatinine ≤  2 × 
ULN, or calculated creatinine clearance >30 ml/minute .  
10. Female patient shall be: a) of non -childbearing potential 
or b) of childbearing potential using reliable contraceptive measures and having a negative urine pregnancy test within [ADDRESS_209374]*. 
Notes:  
a) Female patient of non -childbearing potential is defined as being in 
post-menopausal state since at least 1 year; or having documented 
surgical sterilization or hysterectomy at least 3 months before study 
participation.  
b) Reliable contraceptive measures include implants, injectables, 
combined oral contraceptives, intrauterine devices, vasectomized partner or complete (long term) sexual abstinence . 
11. The patient must be willing and able to comply with the 
protocol tests and pr ocedures . 
All inclusion criteria will be checked at screening visit (Visit 
1). *Inclusion criterion #10 will be re- checked and verified at 
Day 1 (Visit 2). 
Exclusion Criteria  
 1. Patient with other forms of lung cancer (e.g., small cell, 
neuroendocrine tumors ). 
2. Woman who is pregnant or breast- feeding . 
3. Reversible causes of reduced food intake, as determined by [CONTACT_737]
*. These causes may include but are 
not limited to:  
a. NCI CTCAE  Grade 3 or 4 oral mucositis,  
b. NCI CTCAE  Grade 3 or 4 GI disorders [nausea, 
vomiting, diarrhea, and constipation],  
c. mechanical obstructions making patient unable to 
eat, or  
d. severe depression . 
4. Patient undergoing major surgery (central venous access 
placement and tumor biopsies are not considered major 
surgery) within [ADDRESS_209375] be well recovered from acute effects of surgery 
ANAM -17-21  
Final (v5.0 )/[ADDRESS_209376] plans to 
undergo major surgical procedures during the treatment 
period. 
5. Patient currently taking androgenic compounds including but not limited to testosterone, testosterone -like agents, 
oxandrolone,  
Megestrol acetate, 
Corticosteroids [for details see Section 5.13.1] , 
Olanzapi[INVESTIGATOR_050] [for details see Section  5.13.2], 
Mirtazapi[INVESTIGATOR_050] (however, long- term use of mirtazapi[INVESTIGATOR_178219] ), 
Dronabinol, 
Marijuana (cannabis) , or  
Any other prescription medication or off-label products 
intended to increase appetite or treat unintentional 
weight loss
*. 
6. Patient with pleural effusion requiring thoracentesis, 
pericardial effusion requiring drainage, edema or 
evidence of ascites*.  
7. Patient with uncontrolled or signi ficant cardiovascular 
disease, including: 
a. History of myocardial infarction within the past [ADDRESS_209377] degree (may be 
eligible if currently have a pacemaker) , 
c. Unstable angina, 
d. Congestive heart failure within the past 3 months, if 
d
efined as NYHA class III -IV,  
e. Any history of clinically significant ventricular 
arrhythmias [ such as ventricular tachycardia, 
ventricular fibrillation, Wolff -Parkinson- White 
(WPW) syndrome, or torsade de pointes], 
f. Uncontrolled hypertension (blood pressure >150 
mm Hg systolic and >95 mm Hg diastolic) , 
g. Heart rate < 50 beats per minute on pre-entr y 
electrocardiogram and patient is symptomatic*. 
8. Patient on drugs that may prolong the PR or QRS 
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 16 of 110 
CONFIDENTIAL   
 
interval durations, such as any of the antiarrhythmic 
medications Class I (Fast sodium (Na) channel blockers)  
[Additional details are provided in Section 5.13.2] . 
9. Patient unable to readily swallow oral tablets*.   
10. Patient with severe gastrointestinal disease (including 
esophagitis, gastritis, malabsorption).  
11. Patient with history of gastrectomy .  
12. Patient with uncontrolled diabetes mellitus or unmonitored diabetes mellitus . 
13. Patient with cachexia caused by [CONTACT_81466], as determined by [CONTACT_178253]: 
a. Severe COPD requiring use of home O
2,  
b. [LOCATION_001] Heart Association (NYHA) class III -IV 
heart failure (see APPENDIX 8 ), 
c. AIDS , 
d. Uncontrolled thyroid disease. 
14. Patient receiving strong CYP3A4 inhibitors within 14 days of randomization (see APPENDIX 3 ). 
15. Patie nt currently receiving tube feedings or parenteral 
nutrition (either total or partial).   
16. Current excessive alcohol or illicit drug use.  
17. Any condition, including the presence of laboratory abnormalities, which in the Investigator’s opi[INVESTIGATOR_1649], places the subject at unacceptable risk if he/she were to 
participate in the study or confounds the ability to 
interpret data from the study.  
18. Enrollment in a previous study with anamorelin HCl 
19. Patient actively receiving a concurrent investigational agent, or having received an investigational agent within 28 days of Day 1. 
All exclusion criteria will be checked at screening visit 
(Visit 1). 
*Exclusion Criteria #3, 5, 6, 7g, and 9 are to be re-
checked and verified before study drug administration (Visit 2).  
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 17 of 110 
CONFIDENTIAL   
 
Efficacy Assessments  Primary Efficacy Endpoints: 
The co -primary efficacy endpoints are: 
• Mean  change in body weight from baseline over 
12 weeks . 
• Mean  change in 5- item Anorexia Symptom 
Subscale from baseline over  12 weeks . 
Secondary Efficacy Endpoints:  
• Duration of treatment benefit in weight ( ≥0) from 
baseline over 12 weeks . 
• Duration of treatment benefit in weight (≥ to a 
predefined threshold) from baseline over 12 
weeks.  
• Duration of treatment benefit in anorex ia 
symptoms ( ≥0) from baseline  over 12 weeks, as 
measured by [CONTACT_941] 5- item Anorexia Symptom 
Subscale.  
• Duration of treatment benefit in 5 -item Anorexia 
Symptom Subscale (≥ to a predefined threshold)  
from baseline over 12 weeks . 
 
Note: The duration of treatment benefit is measured as the 
duration for which the patient observed a change from 
baseline superior or equal to zero, or to  the predefined 
thresholds of clinical meaningfulness , the latter defined 
through a fully anchor based method using PGIS and PGIC 
as anchors . 
• Mean change in FAACT 12 -item A/CS domain 
from baseline over 12 weeks. 
• Mean change in FACIT -F from baseline over 12 
weeks.  
• Mean change in FAACT total score from 
baseline over 12 weeks. 
 
 
Exploratory Efficacy Endpoints: 
• Mean  change in body weight from baseline up to 
Week 6, 9, 15, 18, 21, and 24. 
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 18 of 110 
CONFIDENTIAL   
 
• Mean change in patient -reported anorexia 
symptom from baseline up to Week 6, 9, 15, 18, 
21, and 24 as measured by [CONTACT_941] 5 -item Anorexia 
Symptom Subscale. 
• Mean change in FAACT total score from baseline 
up to Week 6, 9, 15, 18, 21, and 24. 
• Composite Clinical Response (CCR) at Week 3, 
6, 9, 12, 15, 18, 21, and 24. 
• Change in body weight from baseline to Week 3, 6, 9, 12, 15, 18, 21, and 24. 
• Change in patient -reported anorexia sy mptoms 
from baseline to Week 3, 6, 9, 12, 15, 18, 21, and 24 as measured by [CONTACT_941] 5 -item Anorexia Symptom 
Subscale. 
• Achievement of a clinically meaningful gain in 
body weight from baseline to Week 3, 6, 9, 12, 
15, 18, 21, and 24. 
• Achievement of a clinically meaningful increase 
in 5- item Anorexia Symptom S ubscale from 
baseline to Week 3, 6, 9, 12, 15, 18, 21, and 24. 
• Percentage of change in body weigh t from 
baseline to Week 3, 6, 9, 12, 15, 18, 21, and 24. 
• Changes from baseline to Week 3, 6, 9, 12, 15, 
18, 21, and [ADDRESS_209378] (including FAACT 
total score , FACT -G total score , FAACT TOI, 
the 12- item A/CS domain and the [ADDRESS_209379]).  
• Changes from baseline to Week 3, 6, 9, 12, 15, 
18, 21, and 24 in patient -reported f atigue as 
measured by [CONTACT_178254]- Fatigue (FACIT -F) 
domain as well as the FACIT -F TOI score . 
• Changes from baseline to Week 3, 6, 9, 12, 15, 
18, 21, and 24 in the Hunger Assessment Scale.  
• Changes from baseline to We ek 6 and 9 in the 
Patients’ Global Impression of Severity (PGIS) 
scale and the Patients' Global Impression of 
Change (PGIC) scale at Week 6 and 9.  
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 19 of 110 
CONFIDENTIAL   
 
Safety Assessments  The following safety assessments will be obtained during the 
Study: physical examination (PE), vital signs, 12- lead 
electrocardiogram (ECG), laboratory test (hematology, 
blood chemistry, urinalysis), adverse events (AEs) 
assessment, the overall survival on all patients and tumor 
assessments using CT scan at all sites as per standard local 
practice.   
Stratification  
 Central randomization will be stratified by [CONTACT_178255]-cancer treatment (first line vs second line vs third line), 
by [CONTACT_178256]-cancer therapy (immunotherapy vs non-
immunotherapy) and by [CONTACT_178257] 5- item Anorexia 
Symptom Subs cale (≤10 vs >10) . 
Statistical Analysis of 
Efficacy  
 Analysis Sets 
Statistical analyses will be performed on the following 
patients’ sets: 
• Intent- to-Treat (ITT): all randomized patients will be 
analyzed as per planned treatment . 
• The Full Analysis Set (FAS) includes all 
randomized patients  who take at least one dose of trial 
medication and for which post randomization data are 
collected. The d efinition may be updated at the time of 
the blind review of the data at the end of the trial.  
• Per-Protocol (PP): subset of the randomized patients 
who do not have major protocol violations.  
• Safety: all patients who receive any study drug and will be analy zed as per actual treatment .   
Primary Efficacy Endpoint Hypotheses and Tests  
H
0w: MW a = MW p 
H1w: MW a ≠ MW p 
Where MW a is the mean change of weight for the 
anamorelin arm and MW p is the mean change of  weight for 
the placebo arm.  
H0a: MA a = MA p 
H1a: MA a ≠ MA p 
Where MA a is the mean change of 5- item Anorexia 
Symptom S ubscale score  for the anamorelin arm and MA p is 
the mean change of 5- item Anorexia Symptom Subs cale 
score for the placebo arm.  
The experimental false positive error rate will be preserved 
ANAM -17-21  
Final (v5.0 )/[ADDRESS_209380] component (anamorelin) 
superior to the placebo, both co- primary endpoints must be 
significant, meaning that both H 0w and H 0a must be rejected  
simultaneously. 
The primary efficacy analyses will be conducted on the ITT. 
H0w and H 0a will be tested using an  ANOVA to compare the 
two treatment groups, at a type -I error threshold of 0.[ADDRESS_209381] error (SE) will be 
computed, then pooled usi ng the Rubin rule, the pooled 
difference and the related p -value will be interpreted for the 
primary efficacy analyses . The mean change effect will be 
computed as mean of the changes from baseline over [ADDRESS_209382] assessment (either Week 12 or 
before, for the analysis at W eek 12), and then divided by [CONTACT_178258] (observed or imputed) from baseline 
up to the time of the last assessment (either week 12 or 
before, in case of death, for the analysis at W eek 12).  
The mean change from baseline over 12 w eeks in the 
secondary efficacy endpoints will be analyzed by [CONTACT_178259], and the stratification factors.  
 
Sensitivity Analyses  
A sensitivity analysis reg arding imput ation of  missing will 
be performed using data from the placebo group only 
(control- based imputation) fo r patients who do not have 
properly matched patients with complete follow- up. 
An analysis similar to the primary efficacy analysis will be also conducted after having imputed the 
values  of weight 
obtained in presence of fluid retention.  
 
Supportive Analyses 
Two analyses similar  to the primary efficacy analysis will be 
conducted, one on the FAS population and another one on 
the PP for each of t he primary endpoints. 
Primary efficacy endpoints will be presented for all the 
subgroups (listed in Section  9.4.3).  
 
 
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 21 of 110 
CONFIDENTIAL   
 
Secondary Efficacy Endpoints Hypotheses and Tests   
H0d0w: D0Wa = D 0Wp 
H1d0w: D0Wa ≠ D0Wp 
Where D0Wa is the duration of treatment benefit in weight 
(≥0) for the anamorelin arm  and D 0Wp is the duration of 
benefit in weight for the placebo arm. 
H0dtw: DtWa = D tWp 
H1dtw: DtWa ≠ D tWp 
Where D tWa is the duration of treatment benefit in weight (≥ 
to a predefined threshold) for the anamorelin arm and D tWp 
is the duration of benefit in weight for the placebo arm.  
H0d0A: D0Aa = D 0Ap 
H1d0A: D0Aa ≠ D 0Ap 
Where D 0Aa is the duration of treatment benefit in 5- item 
Anorexia Symptom Subscale (≥0) for the anamorelin arm 
and D 0Ap is the duration of benefit in 5- item Anorexia 
Symptom Subscale for the placebo arm.  
H0dtA: DtAa = D tAp 
H1dtA: DtAa ≠ D tAp 
Where D tAa is the duration of treatment 
benefit in 5-item Anorexia Symptom 
Subscale (≥ to a predefined threshold) for the 
anamorelin arm and D tAp is the duration of 
benefit in 5-item Anorexia Symptom 
Subscale for the placebo arm.H 0mf: MFa = 
MF p 
H1mf: MFTa ≠ M Fp 
Wher e MFa is the mean change in FAACT 12-item A/CS 
domain score in the anamorelin arm and M FTp is the mean 
change in FAACT 12-item A/CS domain  score in the 
placebo arm.  Similar hypothesis systems are set- up for 
FAACT total score ( H0mFt, H1mFt) and FACIT -F (H0mFF, 
H1mFF). 
If the co -primary analysis lead s to rejection of H 0w and H 0a, 
then the following hypothesis will be tested sequentially: 
secondary efficacy endpoint rel ated to the duration of 
treatment benefit in weight (≥0) (H0d0w), the secondary 
efficacy endpoint related to the duration of treatment benefit 
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 22 of 110 
CONFIDENTIAL   
 
in weight (≥ to a predefined threshold) (H0dtw), the secondary 
efficacy endpoint related to the duration of treat ment benefit 
in 5- IASS  (≥0) (H 0d0A), the secondary efficacy endpoint 
related to the duration of treatment benefit in 5 -IASS ( (≥ to a 
predefined threshold) (H 0dtA) and then the secondary efficacy 
endpoint related to the mean change in FAACT 12-item 
A/CS domain  score  (H0mF), FAACT total score and FACIT -
F. Each of these tests will be done sequentially at the level 
of 0.[ADDRESS_209383] on the primary endpoints as well as on the 
secondary endpoints. This will guarantee the study- wise 
type- 1 error, while not requiring any adjustment for multiple 
testing.  
The duration of treatment benefit is measured as  the duration 
for which the patient observed a change from baseline 
superior or equal to zero, or to  the predefined thresholds of 
clinical meaningfulness. For the purpose of computation, it 
will be assumed a linear evolution between two 
measurements . 
 
Exploratory Efficacy Analysis  
The duration of benefit and mean change from baseline 
endpoints will be analyzed like the main analysis for the 
primary efficacy endpoint s or the analyses of the secondary 
endpoints.  
All the change from baseline exploratory endpo ints except 
the HAS and the PGIS/C will be analyzed using an 
ANCOVA model, with explanatory variables being the 
randomized treatment, the stratification factors  and the 
baseline value.   
All the responder analyses (CCR and achievement of 
responder threshold ) will be analyzed using a logistic 
regression, with explanatory variables being the randomized 
treatment, and the stratification factors.  
To explore the correlation between the weight gain and the improvement on the patient -
reported anorexia score, the 
Pearson’s correlation coefficient will be estimated within 
each treatment group.  
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 23 of 110 
CONFIDENTIAL   
 
Statistical Analysis of 
Safety  All safety and tolerability data will be summarized 
descriptively.  
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 24 of 110 
CONFIDENTIAL   
 
STUDY FLOW CHART 
Study Design and Schedule of Assessments (Screening to Week 9)  
Assessment  Screening  Visit Day14 
Treatment Period  
Day -7 to -1 1 22 (+3)  43 (+3)  64 (+3)  
Week  -[ADDRESS_209384] ory X13     
Physical ex am2 X X X X X 
ECOG PS  X    X 
Vital signs X X X X X 
Height and BMI3 X     
Body  weight3 X X X X X 
12-Lead ECG4 X X X X X 
Chemis try/Hemat ology5 X X X X X 
HbA1c  X     
Urine pregnancy6 X X   X 
Urinalysis7 X    X 
Administer FAACT questionnaire 12-item A/CS domain 
only8, 9 X     
Administer FACIT questionnaires (includes all [ADDRESS_209385]-G, 12 -item A/CS 
domain and 13-item FACIT -F fatigue domain) and Hunger 
Assessment Scale questionnaires 
8, [ADDRESS_209386] scan10 X     
Adverse events11 X X X X X 
Prior and c oncomitant medications (including NSCLC 
treatment)12 X X X X X 
Randomization   X    
Disp ense new and/or return  blister card for study drug 
dosing; check comp liance   X X X X 
1 Informed consent will be obtained prior to any study -related screening procedures. Procedures may be 
completed over several visits if desired.   
2 A complete Physical Exam will be conducted and will also focus on evaluation for any signs of pedal 
edema, pericardial effusion, pleural effusions, and ascites . 
3 Height will be measured in cm. Body weight will be measured in kg using a calibrated scale dedicated for 
use in this study, and following study -specific procedures as described in  APPENDIX . 
ANAM -17-21  
Final (v5.0 )/[ADDRESS_209387] a 12 -lead ECG performed in triplicate at 1 hour (±5 minutes) post dose at each visit, 
with the exception of Screening Visit (where ECG will be taken only pre -dose) and Visit 2, Day 1 (where 
ECG will be taken also pre -dose).   Every effort  will be made to perform ECG at the assigned timepoint.  
5 Chemistry and hematology testing will be done under fasting condition. Hematology: CBC with 
differential count. Chemistry: sodium, potassium, chloride, calcium, total protein, albumin and pre -
albumi n, AST (SGOT), alkaline phosphatase (ALP), ALT (SGPT), total bilirubin, creatinine, C -reactive 
protein and glucose.  
[ADDRESS_209388] is to be performed at Visit 2 (Day 1).
 
7 Urinalysis will be performed pre -dose and under fasting conditions and will include: Protein,  glucose, 
WBC, erythrocytes, and bacteria.  
[ADDRESS_209389] their answers, and document details of who completed the survey.
 
9 Preferred order of the ePRO administration at each visit is based on importance of endpoints: At screening visit FAACT foll owed by [CONTACT_178260] . At Week [ADDRESS_209390] -G, FACIT -F, and HAS. At Week 6 and Week 9 visits: FAACT, FACT -G, 
FACIT -F, PGIS  questionnaires for body weight and anorexia , PGIC  questionnaires for body weight , 
anorexia  and overall condition , and HAS. Of note, the FAACT contains 12 items, and 5 of these items will 
be used to score the 5 -item Anorexia Symptom S ubscale and 4 of these items will be used to score the 4 -
item Anorexia Concerns S ubscale (see Section 7.1.2 ). 
[ADDRESS_209391] dose of study drug. Any 
tumor assessment outside of the screening visit will be assessed and recorded ; for details , please see 
Section  7.2.7 .
 
11 Adverse events will be collected from Informed consent signature [CONTACT_178327] 26 
(Visit 11). SAEs must be reported within [ADDRESS_209392] patient blood draws under fasted conditions; fasting status will be documented 
within the CRF. Patients who withdraw from study prematurely will be requested to complete the Day 64 visit (Week 9) procedures.  
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 26 of 110 
CONFIDENTIAL   
 
Study Design and Schedule of Assessments (Week 12 to 26)  
Assessment  Visit Day9 
Treatment Period  Follow -up 
Period10 
(telephone)  
Day 85 (+3)  106 (+3)  127 (+3)  148(+3)  169 (+3)  183 (+3)  
Week  12 15 18 21 24 26 
Visit  6 7 8 9 10 11 
Physical ex am1 X X X X X  
Vital signs X X X X X  
Body  weight2 X X X X X  
12-Lead ECG X X X X X  
Chemis try/Hemat ology3 X X X X X  
HbA1c  X    X  
Urine  preg nancy testing  (wom en of 
childbearing potential only)      X  
Urinalysis4      X  
Administer FACIT questionnaires ( includes 
all [ADDRESS_209393] -G, 12-item A/CS domain and 13 -
item FACIT-F fatigue domain ) and Hunger 
Assessment Scale questionnaires5 X X X X X  
CT scan6 X      
Adverse events7 X X X X X X 
Concomitant medications (including 
chemotherapy)8 X X X X X  
Disp ense new and/or return  blister card for 
study drug dosing; check comp liance  X X X X End  
1 Physical Exam will focus on evaluation for any signs of pedal edema, pericardial effusion, pleural 
effusions, and ascites. 
2 Body weight will be measured in kg using a calibrated scale dedicated for use in this study and following study- specific procedures as described in APPENDIX 2 .
 
3 All tests will be done under fasting condition. Hematology: CBC with differential count. Chemistry: 
sodium, potassium, chloride, calcium, total protein, albumin and pre -albumin, AST (SGOT), alkaline 
phosphatase (ALP), ALT (SGPT), total bilirubin, creatinine, C -reactive protein and glucose.  
4 Urinalysis will be performed pre -dose and under fasting conditions and will include: Protein, glucose, 
WBC, erythrocytes, and bacteria.  
[ADDRESS_209394] local practice for tumor assessment. Any 
tumor assessment o utside of the screening visit will be assessed and recorded ( please see S ection  7.2.7).  
7 Adverse events will be collected from Informed consent signature [CONTACT_178328] 26 (Visit 11, follow -up visit). All SAEs must be reported within 24 hours.
  
8 Adherence to baseline NSCLC treatment regimen and all future regimens will be captured throughout the 
treatment period . 
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 27 of 110 
CONFIDENTIAL   
 
9 On study days t hat coincide with chem otherapy  adm inistr ation,  all study proce dures should be obtained 
prior to adm inistration of chemoth erapy. Patients should arrive for visits prior to dosing, and patient 
blood draws under fasted conditions; fasting status will be documented within the CRF. Patients who 
withdraw prematurely will be requested to complete the Day 183+3 visit (Week 26) procedures . 
10 Follow - up visit on Day 183 +3 (Visit 11) will be conducted by [CONTACT_756] . 
 
ANAM -17-21  
Final (v5.0 )/[ADDRESS_209395] OF ABBREVIATIONS  
A/CS  12-item Additional Concerns Subscale of the FAACT  
ADL  Activities of Daily Living  
AE Adverse Event 
AESI  Adverse Events of Special Interest  
AJCC  American Joint Committee on Cancer  
ALP  Alkaline Phosphatase  
ALT  Alanine transaminase (SGPT)  
ANC  Absolute Neutrophil Count 
AST  Aspartate transaminase (SGOT)  
BDRM  Blind Data Review Meeting  
BMI  Body Mass Index  
CBC  Complete Blood Count  
CCR  Composite Clinical Response  
CI Confidence interval  
CRO  Clinical Research Organization  
CT Computerized Tomography  
CTCAE  Common Terminology Criteria for Adverse Events  
CYP  Cytochrome P450  
EC50  half maximal Effective Concentration  
ECG  Electrocardiogram  
ECOG  Eastern Cooperative Oncology Group  
ECOG PS  Eastern Cooperative Oncology Group Performance Status  
eCRF  Electronic Case Report Form  
EDC  
ePRO  Electronic Data Capture  
Electronic Patient Reported Outcome  
EGFR  Epi[INVESTIGATOR_178220]/Cachexia Treatment  
FACIT  Functional Assessment of Chronic Illness Therapy  
FACIT -F Functional Assessment of Chronic Illness Therapy -Fatigue  
FACT -G Functional Assessment of Cancer Therapy - General  
ANAM -17-21  
Final (v5.0 )/[ADDRESS_209396] at an individual study center .  
Every study center has a principal investigator.  
PK Pharmacokinetic  
ANAM -17-21  
Final (v5.0 )/[ADDRESS_209397] Deviation  
SGOT  Serum Glutamic Oxaloacetic Transaminase (AST)  
SGPT  Serum Glutamic Pyruvic Transaminase (ALT)  
SOC   System Organ Class 
S[LOCATION_003]R  Suspected Unexpected Serious Adverse Reaction  
TEAE  Treatment -Emergent Adverse Event 
TOI Trial Outcome Index  
ULN  Upper limit of normal  
[LOCATION_003]  [LOCATION_002]  of America  
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 31 of 110 
CONFIDENTIAL   
 
1 INTRODUCTION AND RATIONALE  
1.1 Background Information 
Weight loss and anorexia are among the symptoms that characterize cancer cachexia, a 
multifactorial syndrome that occurs in more than 80% of patients with cancer before death [ Kumar -2010; von Haehling-2010; Aoyagi-2015].  
Following the current consensus criteria cancer cachexia is primarily diagnosed either by [Fearon -2011 ]:  
- recent weight loss > 5% over past 6 months (in absence of simple starvation), or  
- recent weight loss > 2% and body-mass index (BMI) <20 kg/m
2, or  
- sarcopenia.  
Reduced food intake in patients with cancer is caused by [CONTACT_178261]; according to a number of reports, cancer patients describe weight loss and anorexia symptoms as sources of concern/worry, with significant impacts on their daily lives [ Hinsley -2007;  Hopkinson-2014;  McGrath -
2002;  Hopkinson-2015;  Oberholzer-2013].  
To better understand the experiences of weight loss/low BMI in lung cancer patients, Helsinn collaborated with PatientsLikeMe [ Rodriguez-2017], an online patient network 
that connects patients and facilitates research. Ninety -five patients participated in an 
online survey, and 35 of them (36.8%) were classified as having considerable weight loss (defi ned as ≥ 5% loss of body weight in the past 6 months or ≥ 2% for a BMI less than 20 
kg/m
2). Weight loss was found to represent a substantial problem for NSCLC patients, 
associated with lower quality of life, higher distress level and more severe symptoms (including appetite loss).  Patients were also asked to identify which symptoms they 
experience because of their weight loss had the most significant impact on their life. For these patients the most frequently reported symptoms with significant impacts wer e 
changes in food taste (38%), fatigue (38%), and decrease in appetite (33%); early satiety, which is another relevant component of anorexia together with food taste and decreased appetite, was also noted as a symptom having a significant impact in 14% of the patients surveyed [ Rodriguez-2017].  
Anorexia is a major contributor to the weight loss. Anorexia in cancer may be characterized as a general loss of appetite, early satiety, altered food preferences, or a combination of these [ Molfino-2015]. Cancer related anorexia is also a major clinical 
problem and adversely influences nutritional status in advanced cancer [ Yavuzsen -2005] 
and has been associated with poorer survival in multiple studies [ Montazeri -2009; 
Sundstrøm-2006; Fielding -2007; McKernan -2008; Collette2004Yeo -2006; Sullivan -
2006]. Anorexia is the second most common symptom after fatigue in patients with advanced cancer [ Lis-2009]. In a study conducted by [CONTACT_178262]. appetite loss 
emerged as the most significant independent indicator for survival in advanced NSCLC patients and concluded that assessment of anorexia, including appetite loss is a valuable tool in determining thoracic radiotherapy strategy [ Sundstrøm-2006].  
ANAM -17-21  
Final (v5.0 )/[ADDRESS_209398] been noted in 
patients with weight loss, which can be of sufficient severity to require dose reductions, 
treatment delays or definitive termination of treatment, such that weight- losing patients 
do not achieve the full potential benefit of their cancer therapy [ Ross -2004; Andreyev -
1998]. Furthermore, in a study in advanced NSCLC patients comparing non-weight 
losing patients to weight losing/underweight patients (≥5% weight loss in prior 6 months 
or >2% weight loss with BMI<20 kg/m2), it was found that all patient -reported outcome 
(PRO) measures (FACT -G and specific domains from FAACT, FACIT -F, FACIT -L) and 
performance status (Karnofsky  PS and ECOG) were worse in the weight 
losing/underweight patients compared to non- weight losing patients, and that while all 
these measures declined over a 6 month period, the rate of decline was more rapid in the weight-losing/underweight group [ LeBlanc-2015 ]. 
In summary, weight loss, along with anorexia (including appetite loss), are common, debilitating, and concerning occurrences for advanced cancer patients. Despi[INVESTIGATOR_178221], there has been a lack of therape utic 
advance in managing these symptoms of advanced cancer patients, and pharmacological interventions remain limited.  
Therefore, the treatment of malignancy associated weight loss and anorexia in cancer 
patients are an area of unmet medical need.  
Anamore lin HCl is an orally -active selective ghrelin receptor agonist. Ghrelin is the 
endogenous ligand for the G -protein- coupled ghrelin receptor, GRLN (formerly known 
as the growth hormone [GH] secretagogue receptor, GHS -R) [ Kojima -1999] . It is 
synthesized predominantly in the stomach and has a short circulating half -life (~15 
minutes) in both animals and humans, which limits its therapeutic potential since long -
term effica cy would necessitate continuous infusion. Nevertheless, research into the 
effects of ghrelin or longer -acting ghrelin mimetics has revealed that ghrelin possesses 
anabolic, appetite -enhancing, adiposity- increasing, and anti -inflammatory properties 
[Guillory -2013]; along with GI- prokinetic activity [ Trudel-2002 ].  
In vitro , anamo relin displays high affinity and selective binding to the ghrelin receptor 
and is a highly potent GH secretagogue by [CONTACT_178263] (EC50 = 1.5 nM). In vivo , 
anamorelin HCl elicited a robust GH release following oral administration to dogs and a potent appetite enhancing effect in rats following intracerebral administration; increases in food intake and body weight were also noted in animal models [ Trudel-2002]. In 
clinical studies, anamorelin treatment is also associated with increases in appetite and body weight, along with gains in lean body mass (LBM) and improvements in health-related QoL measures [ Temel -2016; Currow -2014 ]. 
1.2 Anamorelin: preclinical and clinical data  
1.2.[ADDRESS_209399] over 100 receptors, enzymes, transporters and ion channels. Moreover , cardiovascular and other safety pharmacology 
studies were conducted. Studies were conducted to determine the absorption, distribution, 
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 33 of 110 
CONFIDENTIAL   
 
metabolism and excretion of anamorelin in rats and mice. Toxicology studies were 
carried out in rats and dogs, including single and repeated -dose studies  for up to 26- week 
duration. Additional toxicology studies were performed to evaluate potential effects on fertility in rats, embryo -fetal development in rats and rabbits and assess the effects on 
tumor growth in mice. Overall , these studies allowed to cha racterize the non -clinical 
profile of anamorelin as required to support its clinical development and marketing authorization applications in the future. 
A detailed description of the preclinical data available is provided in the relevant sections 
of the Investigator’s Brochure .   
1.2.2  Phase 1 Clinical Data  
Anamorelin HCl has been studied in 12 Phase 1 studies in healthy volunteers of both 
genders including elderly with dosing up to 400 mg for a single -dose and up to 150 mg 
for multiple -doses. Anamorelin HCl increased GH, insulin- like growth factor -1, and 
insulin -like growth factor binding prote in-3 and produced the desired biologic effects of 
significant appetite stimulation, increase of food intake, body weight gain. The threshold dose for body weight gain is 50 mg once daily (QD). QD dosing in the fasting state is appropriate for anamorelin HCl; a split dose regimen offers no advantage over QD dosing and available data suggest that it may be less efficacious. No dose -limiting toxicity was 
observed up to 150 mg with multiple dosing; a single dose of [ADDRESS_209400] from the Phase 1 studies included increases in serum transaminases and electrocardiogram (ECG) abnormalities including transient PR, QRS and QT prolongations at the supratherapeutic doses of 300 and 400 mg (based on 24- hour Holter 
monitoring data from Study HT -ANAM -112). Of note, none of the QTcF absolute values 
were above 450 ms. The PR, QRS and QT increases were considered not clinically significant by [CONTACT_737]. To better assess the ECG effects of anamorelin HCl, a thorough QT/QTc study (Study HT -ANAM -113) was then conducted, and the overall 
results showed that anamorelin had no meaningful effect on ventricular repolarization. 
1.3 Other Clinical Data  
Anamorelin HCl was additionally evaluated in one Phase 2 program (including four 
studies), and in one Phase 3 program (including two studies) where 361 and 972 patients, 
respectively, were treated for a total of 915 patients with cancer treated with anamoreli n 
HCl.  
Phase 2 program consisted of studies RC -1291- 203/[ADDRESS_209401] -ANAM -207 included 226 patients with NSCLC and 
randomized patients 1:1:1 to placebo, anamorelin HCl 50 mg, or anamorelin HCl 100 mg. 
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 34 of 110 
CONFIDENTIAL   
 
The Phase 2 program demonstrated that anamorelin HCl significantly increased LBM and 
body weight. Treatment with anamorelin HCl at dose levels of 50 mg and 100 mg QD for up to 12 weeks was generally well tolerated. No dose limiting toxicity was observed. 
The Phase 3 ROMANA program consisted of two studies (HT -ANAM -301 and HT -
ANAM -302) and an associated safety extension study (HT -ANAM -303) and together 
evaluated a total of 972 NSCLC patients for up to 24 weeks.  Results from HT -ANAM -301 and HT -ANAM -302 demonstrated that patients assigned to 
anamorelin experienced an increase in lean body mass, body weight and improvement in 
their anorexia/cachexia symptoms compared to those assigned to placebo in both the studies, but no difference in handgrip strength was observed.  
In a Phase 3 , multicenter, open- label, uncontrolled non- Helsinn sponsored clinical study 
conducted in Japan (ONO -7643- 05), at a dose level of 100 mg QD of anamorelin for 12 
weeks, the proportion of patients with cancer cachexia who maintained or gained lean 
body mass was 63.3% (31/49 subjects). Moreover, patients experienced an increase in  
body weight, improved appetite, stimulated protein synthesis, as measured by [CONTACT_178264]-1 and IGFBP -3, and improved the nutritional status, as measured by [CONTACT_178265].  
In another Phase 3 multicenter, open- label, uncontrolled non- Helsinn sponsored clinical 
study conducted in Japan (ONO -7643- 06), at a dose level of 100 mg QD of anamorelin 
for 24 weeks, the increase in  body weight and the improved appetite in patients with 
cancer cachexia were confirmed, and its efficacy was maintained throughout the 24 -week 
treatment period.  
Safety results from Phase 3 ROMANA program indicated that a namorelin HCl was well 
tolerated.   
A positive safety profile was also confirmed in studies ONO -7643- 05 and ONO -7643-06; 
although there w as a high incidence of adverse drug reactions related to the increased 
blood glucose and cardiac function, no event was  indicative of a significant risk. 
Additional information on currently available clinical data is provided in the relevant 
sections of the Investigator’s Brochure . 
The primary purpose of the present ANAM -17-[ADDRESS_209402] 
of anamorelin HCl on body weight and anorexia symptoms in patients with advanced non-small cell lung cancer (NSCLC).  
1.4 Study Rationale  
1.4.1  Rationale for Study Population 
This study will be conducted in adult patients with advanced NSCLC. Patients with NSCLC are being chosen for investigation because of the prevalence of weight loss and anorexia and the prognostic implications of weight loss for these patients including reduced quality of life and increased symptom burden, as well as shortened survival.  
Among patients with NSCLC, those with BMI < 20 kg/m
2 represent a more 
malnourished/at- risk population, which therefore has a more pressing need for an 
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 35 of 110 
CONFIDENTIAL   
 
effective therapy to address weight loss and anorexia symptoms. Therefore ANAM-17-21 
will enroll only patients with BMI < 20 kg/m2 and will also require >2% weight loss over 
the past 6 months to better align with the consensus definition of anorexia -cachexia 
[Fearon -2011 ]. In addition, as this study is investigating improvements in anorexia 
symptoms, patients enrolled must also demonstrate ongoing problems with their appetite/eating.  
1.4.[ADDRESS_209403] the top concerns of these advanced stage patients and there are currently limited treatment op tions. This study will be an adequate and 
well-controlled study designed to demonstrate superiority of anamorelin HCl vs placebo 
on the gain in body weight and improvement in anorexia symptoms.  
A total of 316 patients with advanced NSCLC with cachexia will be randomized 1:[ADDRESS_209404] data over longer treatment duration.   
1.4.3  Rationale for Selected Dose Range  
In this study, 100 mg was selected as the dose of anamorelin HCl. This 100 mg dose had 
been evaluated in previously conducted Phase 3 studies (HT -ANAM -301 and HT -
ANAM -302) in NSCLC patients indicating that it was well tolerated and had a positive 
anabolic effect through both increased body weight and lean mass. An improvement in cancer anorexia symptoms/concerns in patients with NSCLC -C was also observed. In the 
safety extension study (HT -ANAM -303), whereby [CONTACT_178266] -ANAM -
301/302 continued dosing for up to an additional 12 weeks, a 100 mg dose level was also well tolerated, with no new safety signals identified in the longer dosing period. 
Due to the lack of safe and effective treatments for weight loss and anorexia in cancer 
patients with cachexia, placebo treatment will be used in the control group in this study.  
1.5 Rationale for protocol amendment  
Further to FDA advice obtained on the primary endpoints analysis, the Sponsor redefined 
the primary efficacy endpoints to duration of treatment benefit from baseline to W eek 12 
for body weight and anorexia (5- IASS). Based on this new approach a redefinition of the 
secondary and exploratory endpoints was also included. Such changes were implemented 
in protocol v4.0 dated 22 Mar 2021 and 4.A dated 03 Sep 2021.  
However, during the course of the study, an error was disco vered in the algorithm used to 
determine the statistical power for the evaluation of  the duration of treatment benefit 
from baseline to Week 12 for body weight and anorexia (5- IASS) co -primary endpoints.   
Corrected calculations revealed that each trial, with the current planned sample size of 
316 patients, would be underpowered for the 5- IASS endpoint. Indeed, new simulations 
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 36 of 110 
CONFIDENTIAL   
 
correcting for the programming error were performed and these  results confirmed high 
power (over 98%) for the weight -based co -primary endpoint but showed low power for 
the 5 -IASS co -primary endpoint ( between 60% and 70%).  
Based on corrected simulations and calculations, obtaining a n acceptable power would 
require to  at lea st double the sample size.   
At the current stage of the studies, such a huge change in sample size would be of great 
impact for cachectic cancer patients who are looking at anamorelin as the only promising 
investigational agent in development for treating the two important unmet needs of malignancy associated weight loss and anorexia and hopi[INVESTIGATOR_178222].  
The Sponsor endorses the importance of having two adequate and well controlled trials, each achieving statistical significance. To achieve a proper power for the analysis of th e 
5-IASS co -primary endpoint, the Sponsor will perform the analysis by [CONTACT_178267], i.e. , two co -primary endpoints still keepi[INVESTIGATOR_178223] 5- IASS as efficacy variables, but measuring the mean change from 
baseline in replacement of the duration of treatment benefit , as defined based on scientific 
and clinical experts’ feedback  and confirmed as a feasible endpoint by [CONTACT_178268] . 
 
2 STUDY OBJECTIVE S 
2.1 Primary Objectiv e 
To demonstrate superiority of anamorelin HCl vs placebo on the gain in body weight and improvement in anorexia symptoms. 
2.1.1  Estimand  
The analysis to address this objective has been developed in consideration of ICH Topic 
E9(R1) Statistical Principles for Clinical Trials: Note for Guidance on Statistical 
Principles in Clinical Trials [ ICH-1998]. Specifically, we have anticipated two 
intercurrent events: study drug discontinuation and death. We consider appropriate to assess a treatment effect “regardless of” whether patients continue wit h treatment or not. 
Therefore, we will implement a treatment policy estimand. Efforts will be  made to retain  
all patients in study follow -up whether  they have discontinued the study treatment or not. 
The method of data imputation will take into account that patients have discontinued study treatment. Deaths likely will be due to underlying disease. The aim of anamorelin treatment is to increase body weight and improve anorexia symptoms while the patient is 
alive. Hence, it is necessary and sufficient to obtain regular assessments on body weight and anorexia symptoms between randomization and death.  
 
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 37 of 110 
CONFIDENTIAL   
 
2.2 Secondary Objectives 
To evaluate the safety and tolerability of anamorelin HCl, and to further evaluate 
anamorelin efficacy profile.  
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 38 of 110 
CONFIDENTIAL   
 
3 STUDY ENDPOINTS  
3.1 Efficacy En dpoints  
3.1.1  Primary Efficacy Endpoint  
The co -primary efficacy endpoint s are:  
• Mean change in body weight from baseline over 12 weeks. 
• Mean change in 5- item Anorexia Symptom Subscale from baseline over 12 
weeks . 
3.1.2  Secondary Efficacy Endpoints  
The secondary efficacy endpoints are: 
• Duration of treatment benefit in weight (≥0) from baseline over 12 weeks.  
• Duration of treatment benefit in weight (≥ to a predefined threshold) from 
baseline over 12 weeks. 
• Duration of treatment benefit in anorexia symptoms (≥0) from basel ine over 
12 weeks, as measured by [CONTACT_941] 5- item Anorexia Symptom Subscale.  
• Duration of treatment benefit in 5 -item Anorexia Symptom Subscale (≥ to a 
predefined threshold) from baseline over 12 weeks. 
The duration of treatment benefit is measured as the duration for which the patient 
observed a change from baseline superior or equal to zero, or to the predefined thresholds 
of clinical meaningfulness, the latter defined through a fully anchor based method using 
PGIS and PGIC as anchors .  
• Mean change in FAACT 12-item A/CS domain from baseline over 12 weeks. 
• Mean change in FACIT -F from baseline over 12 weeks. 
• Mean change in FAA CT total score from baseline over 12 weeks. 
3.1.3  Exploratory Efficacy Endpoints  
• Mean change in body weight from baseline up to Week 6, 9, 15, 18, 21, and 24. 
• Mean change in patient -reported anorexia symptoms from baseline up to Week 6, 9, 
15, 18, 21, and 24, as measured by [CONTACT_941] 5 item Anorexia Symptom Subscale. 
• Mean change in FAACT tot al score from baseline up to Week 6, 9, 15, 18, 21, and 24. 
• Composite Clinical Response ( CCR) at Week 3, 6, 9, 12, 15, 18, 21, and 24. 
• Change in body weight from baseline to Week 3, 6, 9, 12, 15, 18, 21, and 24. 
• Change in patient -reported anorexia symptoms  from baseline to Week 3, 6, 9, 12, 15, 
18, 21, and 24 as measured by [CONTACT_941] 5 -item Anorexia Symptom Subs cale. 
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 39 of 110 
CONFIDENTIAL   
 
• Achievement of a clinically meaningful gain in body weight from baseline to Week 3, 
6, 9, 12, 15, 18, 21, and 24. 
• Achievement of a clinically meaningful increase in 5- item Anorexia Symptom 
Subscale from baseline to Week 3, 6, 9, 12, 15, 18, 21, and 24. 
• Percentage of change in body weight from baseline to Week 3, 6, 9, 12, 15, 18, 21, and 
24. 
• Changes from baseline to Week 3, 6, 9, 12, 15, 18, 21, and [ADDRESS_209405] 
(including FAACT total score , FACT -G total score , FAACT TOI, the 12 -item A/CS 
domain and the 4-item Anorexia Concerns Subs cale derived from the FAACT).  
• Changes from baseline to Week 3, 6, 9, 12, 15, 18, 21, and 24 in patient -reported 
fatigue as measured by [CONTACT_178269]-
Fatigue (FACIT -F) domain as well as the FACIT -F TOI score . 
• Changes from baseline to Week 3, 6, 9, 12, 15, 18, 21, and 24 in the Hunger 
Assessment Scale.  
• Changes from baseline to Week 6 and 9 in the Patients’ Global Impression of Severity (PGIS) scale and the Patients' Global Impression of Change (PGIC) scale at Week 6 and 9. 
3.2 Safety Assessments  
The following safety assessments will be performed: physical examination (PE), vital signs, 12- lead electrocardiogram (ECG), laboratory test (hematology, blood chemistry, 
urinalysis), adverse events (AEs) assessment, tumor assessment using CT scan and the overall survival on all patients. 
Overall Survival 
• Overall survival up to the end of study (i.e., week 26, follow-up visit). 
Tumor Assessments  
• Change in tumor assessment (overall response categorized into complete response, 
partial response, stable disease and progressive disease) using CT scans at all sites as per standard local practice.  For additional information please refer to S ection 7.2.7. 
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 40 of 110 
CONFIDENTIAL   
 
4 STUDY PLAN 
4.1 Study Design  
The study is a multicenter, randomized, double -blind, parallel -group, placebo-controlled 
study to evaluate the efficacy and safety of anamorelin HCl. Approximately 316 patients 
with advanced NSCLC with cachexia will be randomized 1:1 to anamorelin HCl 100 mg 
or placebo, taken orally once daily (QD) for a total of [ADDRESS_209406] meal of the day.  
Central randomization will be stratified by [CONTACT_178255]- cancer treatment (first 
line vs second line vs third line), by [CONTACT_178256] -cancer therapy (immunotherapy vs non -
immunotherapy) and by [CONTACT_178257] 5- item Anorexia Symptom S ubscale (≤10 vs 
>10). Patients will visit the site every [ADDRESS_209407] line treatment in IWRS . 
4.2 Study Duration  
Each patient will stay on study for a maximum of 27 Weeks (including 1 week screening 
period and 2 weeks follow -up period). 
Total number of visits per patient: [ADDRESS_209408] for follow-up visit. 
The study will be approximately 27 Weeks in duration including the following:  
• A screening period from Day -7 to -1 (on- site Visit 1)  
• A 24 -week treatment period (on -site Visit 2 to Visit 10)  
• A 2-week follow-up period (telephone Visit 11) 
A patient will be defined as having completed the Study if patient completes the follow -
up visit (Visit 11).  
The overall study completion date is defined as the date of last patient’s last visit or 
telephone contact. 
4.3 Study population 
4.3.1  N umber of Subjects  
A total of 316 patients with advanced NSCLC with cachexia will be randomized 1:1 to 
anamorelin HCl 100 mg or placebo (158 patients per treatment arm). 
4.3.2  Inclusion Criteria  
1. Signed written informed consent. 
2. Female or male ≥18 years of age . 
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 41 of 110 
CONFIDENTIAL   
 
3. Documented histologic or cytologic diagnosis of American Joint Committee on 
Cancer (AJCC) Stage III or IV NSCLC. Stage III patient must have unresectable 
disease. 
4. Body mass index < 20 kg/m 2 with involuntary weight loss of >2% within 6 months 
prior to screening. 
5. Ongoing problems with appetite/eating associated with the underlying cancer, as determined by [CONTACT_178252] ≤ 17 points on the 5- item Anorexia Symptom Scale 
and ≤ [ADDRESS_209409] A/CS . 
6. Patient receiving or not receiving systemic anti -cancer treatment at the time of 
screening are eligible to participate. Systemic anti- cancer treatment includes first, 
second, third treatment line with chemotherapy/radiation therapy, immunotherapy or target ed therapy.   
Patient not receiving anti- cancer treatment is eligible if: 
a. Not planning to receive anti- cancer treatment and/or at least [ADDRESS_209410] be 
elapsed from the completion of prior treatment at the day of screening, in case 
underwent previous cycle,  
OR 
b. Planning to receive anti-cancer treatment within 14 days from randomization 
and/or at least [ADDRESS_209411] be elapsed from the completion of prior treatment at the day of screening, in case underwent previous cycle, 
OR 
c. Patient on palliative care treatment . 
7. ECOG performance status 0,  1 or 2 at screening (see protocol APPENDIX 1 ) 
8. AST (SGOT) and ALT (SGPT) ≤ [ADDRESS_209412] or if hepatic metastases are present ≤ [ADDRESS_209413]. 
9. Adequa te renal function, defined as creatinine ≤2 × ULN, or calculated creatinine 
clearance >30 ml/minute.  
10. Female patient shall be: a) of non -childbearing potential or b) of childbearing 
potential using reliable contraceptive measures and having a negative urine pregnancy test within [ADDRESS_209414]
* 
Notes:  
a) Female patient of non -childbearing potential is defined as being in post -menopausal state since at 
least 1 year; or having documented surgical sterilization or hysterectomy at least 3 months before 
study participation.  
b) Reliable contraceptive measures include implants, injectables, combined oral contraceptives, 
intrauterine devices, vasectomized partner or complete (long term) sexual abstinence.  
11. The patient must be willing and able to comply with the protocol tests and 
procedures.  
All inclusion criteria will be checked at screening visit (Visit 1).  
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 42 of 110 
CONFIDENTIAL   
 
*Inclusion criterion #10 will be re- checked and verified at Day 1 (Visit 2).  
4.3.3  Exclusion Criteria  
1. Patient with other forms of lung cancer (e.g., small cell, neuroendocrine tumors).  
2. Woman who is pregnant or breast- feeding . 
3. Reversible causes of reduced food intake, as determined by [CONTACT_737] *. These 
causes may include, but are not limited to: 
a. NCI CTCAE  Grade 3 or 4 oral mucositis, 
b. NCI CTCAE  Grade 3 or 4 GI disorders [nausea, vomiting, diarrhea, and 
constipation], 
c. mechanical obstructions making patient unable to eat, or 
d. severe depression . 
4. Patient undergoing major surgery (central venous access placement and tumor 
biopsies are not considered major surgery) within [ADDRESS_209415] plans to undergo major surgical procedures during the treatment period . 
5. Patient currently taking androgenic compounds including but not limited to testosterone, testosterone-like agents, oxandrolone; 
Megestrol acetate;  
Corticosteroids [for details see Section 5.13.1]; 
Olanzapi[INVESTIGATOR_050], m irtazapi[INVESTIGATOR_050] (however, long-term use of mirtazapi[INVESTIGATOR_178224]); Dronabinol;  Marijuana (cannabis) , or  
Any other prescription medication or off -label products intended to increase appetite 
or treat unintentional weight loss
* 
6. Patient with pleural effusion requiring thoracentesis, pericardial effusion requiring 
drainage, edema or evidence of ascites* 
7. Patient with uncontrolled or significant cardiovascular disease, including: 
a. History of myocardial infarction within the past [ADDRESS_209416] degree (may be eligible if currently have a 
pacemaker)  
c. Unstable angina 
d. Congestive heart failure within the past 3 months, if defined as NYHA class III-IV
  
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 43 of 110 
CONFIDENTIAL   
 
e. Any history of clinically significant ventricular arrhythmias [such as ventricular 
tachycardia, ventricular fibrillation, Wolff-Parkinson-White (WPW) syndrome, 
or torsade de pointes] 
f. Uncontrolled hypertension (blood pressure >150 mm Hg systolic and >95 mm 
Hg diastolic)  
g. Heart rate < 50 beats per minute on pre- entr y electrocardiogram and patient is 
symptomatic .* 
8. Patient o n drugs that may prolong the PR or QRS interval durations, such as any of 
the antiarrhythmic medications Class I (Fast sodium (Na) channel blockers)  
9. Patient unable to readily swallow oral tablets*.   
10. Patient with severe gastrointestinal disease (including esophagitis, gastritis, 
malabsorption).  
11. Patient with history of gastrectomy .  
12. Patient with uncontrolled diabetes mellitus or unmonitored diabetes mellitus .  
13. Patient with cachexia caused by [CONTACT_81466], as determined by [CONTACT_178253]: 
a. Severe COPD requiring use of home O
2,  
b. [LOCATION_001] Heart Association (NYHA) class III -IV heart failure  
c. AIDS  
d. Uncontrolled thyroid disease. 
14. Patient receiving strong CYP3A4 inhibitors within 14 days of randomization (see APPENDIX 3 ) 
15. Patient currently receiving tube feedings or parenteral nutrition (either total or partial) .   
16.  Current excessive alcohol or illicit drug use.  
17. Any condition, including the presence of laboratory abnormalities, which in the Investigator’s opi[INVESTIGATOR_1649], places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.  
18. Enrollment in a previous study with anamorelin HCl. 
19. Patient actively receiving a concurrent investigational agent or having received an investigational agent within 28 days of Day 1. 
All Exclusion Criteria should be checked at the day of screening visit (Visit 1).  
*Exclusion Criteria #3, 5, 6, 7g, and 9 ar e to be re- checked and verified before study drug 
administration (Visit 2).  
ANAM -17-21  
Final (v5.0 )/[ADDRESS_209417]  
Name:  [CONTACT_178329]:  Tablets  
Strength: [ADDRESS_209418] meal of the day  
Route of 
administration:  Oral 
Placebo  
Name:  [CONTACT_178330] 100 mg tablets  
Dosage form:  Tablets  
Strength: N/A 
Dosing:  At least [ADDRESS_209419] meal of the day  
Route of 
administration:  Oral 
5.2 Treatment Groups  
Group 1 / Test group – 100 mg anamorelin HCl 
Group 2 / Control group – Placebo  
5.[ADDRESS_209420]: Anamorelin HCl  
Patients will take 1 tablet on Day 1 and daily thereafter. Patients will be supplied with 
study drug at visit 2 and re supplied at Visit 3 (Week 3), Visit 4 (Week 6), Visit 5 (Week 9), Visit 6 (Week 12), Visit 7 (Week 15), Visit 8 (Week 18) and Visit 9 (Week 21). Tablets of study drug will be taken orally in mornings while fasting at least [ADDRESS_209421]. Water is  permitted prior to and with study drug. 
5.4 Packaging, Labelling and Shipment  
Study drug will be primary packed in the form of blisters; this will be secondary packed in form of carton wallet cards. Each wallet card will contain either [ADDRESS_209422] be stored in a locked storage area under controlled environmental 
ANAM -17-21  
Final (v5.0 )/[ADDRESS_209423]. Anamorelin HCl tablets and placebo tablets 
should be stored at 20°C -25°C (68°F- 77°F); excursions permitted between 15°C and 
30°C (59°F-86°F). 
5.[ADDRESS_209424] be 
maintained throughout the study.  
Used study kits will undergo drug accountability performed by [CONTACT_178270]. 
Following drug accountability, used study ki ts are to be retained at the site until study 
end. Used and unused study kits remaining at sites at the end of the study will be returned 
to the drug depots for destruction.  
In case the site is strictly required by [CONTACT_178271], site is 
authorized to destroy them locally, following site destruction procedure, only after accountability done and authorization provided by [CONTACT_2728].   
A detailed description of study drug handling will be provided in Study D rug M anual.  
5.8 Administr ation of Study Treatment  
At Day 1 (Visit 2), after confirming patient’s eligibility, the Investigator or designee will 
get connected to the IWRS to randomize the patient. An IWRS will be employed for the randomization activities taking into account the str atification factors (See S ection  9.1). 
The IWRS will assign a study kit number to the patient and the Investigator (or Investigator’s designee) will receive the IWRS notification mentioning the study kit number assigned to the patient for which the request was made. The hospi[INVESTIGATOR_98341], or designated responsible person, will select from the study kits stored at the site pharmacy the corresponding kit as indicated by [CONTACT_178272] -in the blank space(s) 
on the outer study kit label with the patient’s identification number which was assigned by [CONTACT_178273].  
Allocation and distribution of the study kit to the Investigator or Investigator’s designee 
is tracked by [CONTACT_178274] -off portion onto the study site drug 
accountability log (or similar document).  
Adequate written instructions (in form of a Study Drug Manual) for use for the 
pharmacist or designated person will be provided to him/her for the management of the study kit at each study site. 
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 46 of 110 
CONFIDENTIAL   
 
The relevant labels on the study kits will be filled in according to the provided 
instructions. 
Patients will take 1 tablet on Day 1 (if a fasting state is not possible on Day 1, the patient 
will start study drug on Day 2) and daily thereafter.  Patients will be supplied with study drug at Visit 2 and resupplied at Visit 3 (Week 3), Visit 4 (Week 6), Visit 5 (Week 9), Visit 6 (Week 12), Visit 7 (Week 15), Visit 8 (Week 18) and Visit 9 (Week 21).  
Tablets of study drug will be taken orally in mornings while fasting at least [ADDRESS_209425]. Water is permitted prior to and with study drug. 
5.9 Blinding 
This is a double -blind study. The blinding of the study drugs is guaranteed by [CONTACT_178275].   
As far as possible, without compromising patient safety the Investigator may discuss the 
case with the medical monitor prior to breaking the blind. The Investigator has in any case unrestricted and immediate access to break the treatment code, and irrespective of the medical monito r’s advice. If the treatment code is broken, the Investigator(s) must 
document and report it to Sponsor within 24 hours. 
Any unblinding of the study treatment will be performed by [CONTACT_10966] (24- hour 7-day 
coverage). If the code is broken by [CONTACT_737], the patient should be discontinued 
from the study drug, but every effort will be made to collect data from the protocol -
specified assessments as detailed in Section 6.3. The unblinding procedure will be 
detailed in the IWRS manual that will be provided separately to the Investigator. 
The Drug safety officer may proceed to unblinding. The unblinding procedure will be 
managed through the IWRS. The patient  will not be discontinued from the study 
treatment. No notification of unblinding will be disclosed.   
5.10 Treatment Assignment and Randomization - Use of IWRS  
Randomization will be used to avoid bias in assigning treatments to patients. 
Randomization tends to produce treatment groups in which the distributions of prognostic factors, known and unknown are similar; it also enhances the validity and the efficiency of statistical comparisons between the treatment groups.  
The 5 -item Anorexia Symptom S ubscale score will be read from electronic diary then 
entered into the IWRS.  
Central randomization in a double -blind manner will stratify patients using strata defined 
in Section 9.1.  
5.11 Management of Treatment Overdosage  
In case of overdose, conservative management of signs and symptoms is advised. No 
case of over -dosage has been reported with anamorelin to date. No antidote for 
anamorelin overdose is known. Supratherapeutic doses of up to 400 mg were 
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 47 of 110 
CONFIDENTIAL   
 
administered in two phase 1 studies ( one dose escalation study and one QT/QTc study). 
No clinically relevant ECG abnormalities were recorded for doses up to [ADDRESS_209426] dose of study drug.   
Use of diuretics and changes in diuretics use will be collected and recorded at each visit.  
Prophylactic infusion of saline or other hydration solutions prior to or after chemotherapy 
in order to prevent toxic reactions related to chemotherapy is to be recorded on the appropriate eCRF page; this should also include rehydration events that occur outside of the clinical site.  
Infusion of blood products is to be recorded. 
All medications administered in relation to diagnostic procedures, e.g., anesthetics and 
antibiotics are not to be recorded.  
5.13.1  Use of corticosteroids 
Corticosteroids are permitted for a maximum of 5 consecutive days per each chemotherapy and/or radiation cycle if administered as co -medication in chemotherapy 
and/or radiotherapy protocols and for any use other than “appetite st imulant”.  
As well, even single intake of corticosteroids to increase appetite or treat unintentional weight loss is not permitted.  
Inhaled steroids for respi[INVESTIGATOR_178225].    
5.13.[ADDRESS_209427] CYP2D6. The use of strong CYP3A4 inhibitors is an exclusion criterion and drugs known to strongly inhibit CYP3A4 (ketoconazole, clarithromycin, itraconazole, nefazodone, telithromycin) should be avoided two weeks prior to study entry and throughout the trial. If a patient is required to take a strong CYP3A4 inhibitor while enrolled in this trial, then anamorelin dosing must be discontinued. Although moderate or weak CYP3A4 inhibitors may be used, they should be avoided when possible. V erapamil although listed a s 
moderate CYP3A4 inhibitor  (see APPENDIX 3), is not allowed at any time during the 
course of the study as may prolong PR intervals . Furthermore, the concomitant 
admini stration of anamorelin with strong CYP3A4 inducers such as rifampi[INVESTIGATOR_178226] -17-21  
Final (v5.0 )/[ADDRESS_209428]. See A PPENDIX 
3.  
Systematic long -term application of topi[INVESTIGATOR_178227].  Drugs that 
may prolong the PR or QRS interval durations, such as any of the antiarrhythmic 
medications Class I (Fast sodium (Na) channel blockers) are prohibited for the study duration. 
The use of beta- blockers agents to control hypertension could be allowed only for those 
drugs that do not interfere with PR and QRS interval ; sotalol, being classified as class III 
antiarrhythmic agent and also as beta-blocker, is to be avoided [ Yap-2003]. Other beta -
blockers, like nebivolol or metoprolol , could be allowed  if hypertension is controlled 
before entering the study.  Patients should not take any prescription medication or off -label products intended to 
increase appetite or treat unintentional weight loss during the study; these include, but are 
not limited  to, androgenic compounds (including but not limited to testosterone, 
testosterone- like agents, oxandrolone ), megestrol acetate, corticosteroids  (please see 
Section 5.13.1 for regulation regarding use of corticosteroids), dronabinol or marijuana 
(cannabis).  
The recently released version of NCCN guidelines [ NCCN guidelines on antiemesis 
version 2.2020] for CINV prophylaxis has introduced the possibility to use olanzapi[INVESTIGATOR_178228]; the recommended dose is 5 -10 mg on day 1- 4 as used in  
the phase 2 -3 trials [ Navari -2016]. Although weight gain has been reported as side effect 
of olanza pi[INVESTIGATOR_178229] s trials [Allison -2001] , it has not been observed in 
oncology trials and, consequently, its use as part of the CINV prophylaxis is admitted. 
Based on the above, the use of olanz api[INVESTIGATOR_178230].  
Use of mirtazapi[INVESTIGATOR_178231], however, mirtazapi[INVESTIGATOR_178232] 4 weeks prior to screening. 
Patients should not be on treatment with methylphenidate ; tube feeding at the time of the 
study start and during the study is forbidden.   
 
5.13.3  Concurrent NSCLC Treatment  
Depending on the genetic variant and on the treatments’ lines, anti- cancer treatment for 
type and stage of NSCLC, proposed anticancer treatment includes the use of platinum - 
and non- platinum- based chemotherapy, immune checkpoint inhibitors therapy and 
targeted therapy as per NCCN guidelines [ NCCN -2018].  
Details on the allowed treatments are listed below:  
1. Patients on chemotherapy and/or radiation therapy 
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 49 of 110 
CONFIDENTIAL   
 
• This includes patients initiating/planning to initiate c hemotherapy and/or 
radiation therapy within ±14 days of randomization. 
• This also includes patients receiving maintenance chemotherapy. For these 
patients, they should continue maintenance chemotherapy as indicated during 
the study.  
• For all patients receiv ing chemotherapy, if study visits coincide with 
chemotherapy administration, all study procedures should be performed prior to administration of chemotherapy.  
2. Patients on immunotherapy 
• This includes patients initiating/planning to initiate PD -1/PD- L 1 inh ibitor 
regimens within ±14 days of randomization. 
3. Patients on Targeted therapy • This includes patients initiating/planning to initiate targeted therapy regimens 
within ±14 days of randomization. 
4. Patients currently not taking any treatment for their NSCLC  
• This includes patients on palliative care treatment. 
If the primary treatment for NSCLC is changed, interrupted, or permanently discontinued during the planned duration of this trial, therapy with anamorelin HCl or placebo will continue until completion of this study.  
Treatment with all chemotherapeutic and targeted agents should be given in accordance 
with the manufacturer’s warnings and directions and recorded as concomitant medication. Treatment for NSCLC should not be held or delayed in order to begin this trial.  
5.13.4  Use of contraceptive measures  
Female patient of childbearing potential or male patients of fathering potential shall use 
reliable contraceptive measures for the whole duration of the study and until V isit 11 
(Week 26). Reliable contraceptive measures include implants, injectables, combined oral 
contraceptives, intrauterine devices, vasectomized partner , condoms, spermicide or 
complete (long term) sexual abstinence.  
5.14 Rescue Medication  
Not applicable.  
5.15 Treatment Compliance  
Patients will be instructed to bring all blister cards to each study visit during the treatment period for a compliance/accountability check. A patient will be considered to be compliant with therapy if s/he takes all study drugs provided. Compliance will be defined 
overall.  
ANAM -17-21  
Final (v5.0 )/[ADDRESS_209429] 
6.1 Study Procedures by [CONTACT_24326]  
6.1.1  Visit 1 (Screening, Day - 7 to Day - 1) 
If the Investigator considers a patient to be potentially eligible for the study, written 
informed consent for participation in the study must be obtained before any study- related 
procedures starts . The patient will be screened within 7 days prior to randomization (Day 
1) and study drug administration; the following procedures will be performed, and data 
collected during this visit for eligibility pur poses: 
• Informed consent. 
• Significant medical history . 
• A dedicated physical examination with focus to monitoring signs and symptoms of edema (see Section [IP_ADDRESS] for details); Results of this PE will be inserted in source 
data and in the relevant pages of eCRF . 
• ECOG Performance Status . 
• Vital signs (including pulse rate, systolic and diastolic blood pressure after at least [ADDRESS_209430] in semi-supi[INVESTIGATOR_2547], respi[INVESTIGATOR_12876]). 
• Body weight, height and BMI. 
• Prior body weight loss will be verified by [CONTACT_178276]; this 
information can be retrieved either by [CONTACT_2360][INVESTIGATOR_178233]. 
• 12-Lead ECG, in triplicate . 
• Chemistry and hematology testing, including HbA1c under fasting conditions.  
• Urine pregnancy test for females of childbearing potential . 
• Urinalysis under fasting status. 
• Administration of FAACT 12- item A/CS domain and PGIS questionnaires for body 
weight and anorexia. 
• CT scan for tumor assessment . The baseline tumor assessment may  have been 
obtained within [ADDRESS_209431] dose of study drug (see Section 7.2.7). 
• AEs will be collected from the Informed consent signature [CONTACT_178331]- up visit . 
• Prior and concomitant medications data will be collected .  
Based on the relevant above mentioned assessments outcome, the Investigator will decide 
if the patient is eligible for the study. If eligible, patient will be reminded to come back to clinical site under fasting condition for Visit 2 for laboratory assessments and to be administered with study drug. 
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 51 of 110 
CONFIDENTIAL   
 
6.1.2  Visit  2 (Randomization/Treatment Period, Day 1): Week 1  
Patient will arrive at the clinical site under fasting condition. Once at the site, Investigator 
or designated personnel will re-check the following criteria: 
• inclusion criterion # 10 (Urine pregnancy test) and  
• exclusion criteria # 3, 5, 6, 7g, 9. 
If patient is confirmed eligible, authorized study personnel will proceed with 
randomization procedures. The IWRS will provide the study kit number to be dispensed to the patient only after  all the following pre -dose assessments are completed for 
baseline measurements:  
• Laboratory assessments, including:  
o Chemistry , 
o Hematology. 
• Body weight via scale measurement, to be done prior to study drug administration. 
• 12-Lead ECG pre dose, in tripli cate. 
• A dedicated physical examination with focus to monitoring signs and symptoms of edema (see Section [IP_ADDRESS] for details); results of this PE will be inserted in source 
data and in the relevant pages of eCRF . 
• Vital signs ( including pulse rate, systolic and diastolic blood pressure after at least [ADDRESS_209432] in semi-supi[INVESTIGATOR_2547], respi[INVESTIGATOR_12876]). 
• Adverse events recording. 
• Prior and concomitant medications (not including NSCLC treatment) recording. 
• Administration and completion of: 
o FACIT questionnaires (includes all [ADDRESS_209433] -G, 12-item A/CS domain and 13- item FACIT -F fatigue domain), 
o Hunger Assessment Scale questionnaire. 
• Once completed these pre- dose assessments the patient will be “randomized” and 
new study kit will be dispensed.  
• CT scan for tumor assessment. The baseline tumor assessment m ay have been 
obtained within [ADDRESS_209434] dose of study drug (see Section 7.2.7). 
• Study drug will therefore be administered. The date and the precise time (hh:mm) of the study drug must be recorded in the source records as well as on the relevant eCRF page.  
• One hour post study drug administration patient will undergo ECG measurement in triplicate.  
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 52 of 110 
CONFIDENTIAL   
 
• NSCLC treatment regimen will be collected at Baseline and any dose adjustments, as 
and if applicable. 
• Before leaving the clinic, the patient will be reminded about the prohibited 
concomitant medications (see Section 5.13.2 for details).  
• Patient will also be reminded to come back to clinical site in 3 weeks for next visit and be reminded to arrive at the hospi[INVESTIGATOR_178234]. 
6.1.3  Visit 3 (Day 22+3): Week 3  
The patient will return to the trial site on Visit 3, at Day 22 (+3), approximately 3 weeks after Visit 2. Patient will arrive at the hospi[INVESTIGATOR_178234].  
The patient will undergo the following procedures/assessments: 
• Study drug administration . 
• Laboratory assessments, including:  
o Chemistry , 
o Hematology.  
• Vital signs including pulse rate, systolic and diastolic blood pressure after at least [ADDRESS_209435] in semi-supi[INVESTIGATOR_2547], respi[INVESTIGATOR_12876]). 
• Body weight via scale measurement, to be done prior to study drug administration. 
• A dedicated physical examination with focus to monitoring the signs and symptoms 
of edema (see Section [IP_ADDRESS] for details); results of this PE will be inserted in source 
data and in the relevant pages of eCRF . 
• 12-Lead ECG ([ADDRESS_209436] dose), in triplicate.  
• Adverse Events, procedures, and hospi[INVESTIGATOR_178235]. 
• Administration and completion of  
o FACIT questionnaires (includes all [ADDRESS_209437]-G, 12- item A/CS domain and FACIT -F fatigue domain), 
o Hunger Assessment questionnaire.  
Questionnaires will be administered in the order presented here and administered from [ADDRESS_209438] study drug administration. 
• CT scan may be performed as per standard local practice. Exact time point for CT 
scan will depend on the investigator’s standard plan at each site (see Section 7.2.7). 
• Check and record concomitant medications (not including NSCLC treatment regimen) . 
• NSCLC treatment regimen and any dose adjustments, as and if applicable.  
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 53 of 110 
CONFIDENTIAL   
 
• New study kit will be dispensed, and patient will return wallet card from previous 
visit; compliance will be checked . 
• The patient will also be reminded about the prohibited concomitant medications (see 
Section 5.13.2 for details) . 
• Patient will also be reminded to come back to clinical site in 3 weeks for next visit 
and be reminded to arrive at the hospi[INVESTIGATOR_178234]. 
6.1.4  Visit 4 (Day 43+3days): Week 6  
The patient will return to the trial site on Visit 4, at Day 43 (+3), approximately 3 weeks after Visit 3. Patient will arrive at the hospi[INVESTIGATOR_178234] . 
The patient will undergo the following procedures/assessments: 
• Study drug administration . 
• Laboratory assessments, including:  
o Chemistry , 
o Hematology. 
• Vital signs including pulse rate, systolic and diastolic blood pressure after at least [ADDRESS_209439] in semi-supi[INVESTIGATOR_2547], respi[INVESTIGATOR_12876]). 
• Body weight via scale measurement, to be done prior to study drug administration. 
• A dedicated physical examination with focus to monitoring signs and symptoms of 
edema (see Section [IP_ADDRESS] for details); Results of this PE will be inserted in source 
data and in the relevant pages of eCRF . 
• 12-Lead ECG ([ADDRESS_209440] dose), in triplicate. 
• CT scan may be performed as per standard local practice. Exact time point for CT 
scan will depend on the investigator’s standard plan at each site (see Section 7.2.7). 
• Adverse Events, procedures, and hospi[INVESTIGATOR_178235].  
• Administration and completion of  
o FACIT questionnaires (includes all [ADDRESS_209441]-G, 12- item A/CS domain and FACIT -F fatigue domain),  
o PGIS and PGIC questionnaires for body weight, anorexia and overall conditions, 
o Hunger Assessment questionnaire.  
Questionnaires will be administered in the order presented here and administered from [ADDRESS_209442] study drug administration.  
• Check and record Concomitant medications (not including NSCLC treatment 
regimen) .  
• NSCLC treatment regimen and any dose adjustments, as and if applicable. 
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 54 of 110 
CONFIDENTIAL   
 
• New study kit will be dispensed, and patient will return wallet card from previous 
visit; compliance will be checked . 
• The patient will also be reminded about the prohibited concomitant medications (see 
Section 5.13.2 for details ). 
• Patient will also be reminded to come back to clinical site in 3 weeks for next visit and be reminded to arrive at the hospi[INVESTIGATOR_178234]. 
6.1.5  Visit 5 (Day 64+3 days): Week 9  
The patient will return to the trial site on Visit 5, at Day 64 (+3), approximately 3 weeks after Visit 4. Patient will arrive at the hospi[INVESTIGATOR_178234].  
The patient will undergo the following procedures/assessments: 
• Study drug administration. 
• Laboratory assessments, including:  
o Chemistry , 
o Hematology.  
• Urine pregnancy test for females of childbearing potential . 
• Urinalysis under fasting status. 
• Vital signs including pulse rate, systolic and diastolic blood pressure after at least [ADDRESS_209443] in semi-supi[INVESTIGATOR_2547], respi[INVESTIGATOR_12876]). 
• ECOG PS . 
• Body weight via scale measurement, to be done prior to study drug administration. 
• A dedicated physical examination with focus to monitoring signs and symptoms of edema (see S ection [IP_ADDRESS] for details); results of this PE will be inserted in source 
data and in the relevant pages of eCR F. 
• 12-Lead ECG ([ADDRESS_209444] dose), in triplicate. 
• CT scan may be performed as per standard local practice. Exact time point for CT scan will depend on the investigator’s standard plan at each site (see Section 7.2.7). 
• Adverse Events, procedures, and hospi[INVESTIGATOR_178235].  
• Administration and completion of  
o FACIT questionnaires (includes all [ADDRESS_209445]-G, 12- item A/CS domain and FACIT -F fatigue domain).  
o PGIS and PGIC questionnaires for body weight, anorexia and overall conditions. 
o Hunger Assessment questionnaire.  
Questionnaires will be administered in the order presented here and administered from [ADDRESS_209446] study drug administration. 
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 55 of 110 
CONFIDENTIAL   
 
• Check and record Concomitant medications (not including NSCLC treatment 
regimen) .  
• NSCLC treatment regimen and any dose adjustments, as and if applicable. 
• New study kit will be dispensed, and patient will return wallet card from previous 
visit; compliance will be checked . 
• The patient will also be reminded about the prohibited concomitant medications (see Section 5.13.2 for details ). 
• Patient will also be reminded to come back to clinical site in 3 weeks for next visit and be reminded to arrive at the hospi[INVESTIGATOR_178234]. 
6.1.6  Visit 6 (Day 85+3): Week 12  
The patient will return to the trial site on Visit 6, at Day 85 (+3), approximately 3 weeks after Visit 5. Patient will arrive at the hospi[INVESTIGATOR_178234] . 
The patient will undergo the following procedures/assessments: 
• Study drug administration. 
• Laboratory assessments, including:  
o Chemistry , 
o Hematology,  
o HbA1c Assessment . 
• Vital signs including pulse rate, systolic and diastolic blood pressure after at least [ADDRESS_209447] in semi-supi[INVESTIGATOR_2547], respi[INVESTIGATOR_12876]). 
• Body weight via scale measurement, to be done prior to study drug administration. 
• A dedicated physical examination with focus to monitoring signs and symptoms of 
edema (see Section [IP_ADDRESS] for details); Results of this PE will be inserted in source 
data and in the relevant pages of eCRF . 
• 12-Lead ECG ([ADDRESS_209448] dose), in triplicate. 
• CT scan may be performed as per standard local practice. Exact time point for CT scan will depend on the investigator’s standard plan at each site (see Section 7.2.7). 
• Adverse Events, procedures, and hospi[INVESTIGATOR_178235].  
• Administration and completion of  
o FACIT questionnaires (includes all [ADDRESS_209449]-G, 12- item A/CS domain and FACIT -F fatigue domain),  
o Hunger Assessment questionnaire.  
Questionnaires will be administered in the order presented here and administered from [ADDRESS_209450] study drug adminis tration . 
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 56 of 110 
CONFIDENTIAL   
 
• Check and record Concomitant medications (not including NSCLC treatment 
regimen) .  
• NSCLC treatment regimen and any dose adjustments, as and if applicable. 
• CT scan at all sites as per standard local practice. 
• New study kit will be dispensed, and pa tient will return wallet card from previous 
visit; compliance will be checked . 
• The patient will also be reminded about the prohibited concomitant medications (see Section 5.13.2 for details ). 
• Patient will be reminded to come back to clinical site in 3 weeks for next visit and be reminded to arrive at the hospi[INVESTIGATOR_178234]. 
6.1.7  Visit 7 (Day 106+3): Week 15  
The patient will return to the trial site on Visit 7, at Day 106 (+3), approximately 3 weeks after Visit 6. Patient will arrive at the hospi[INVESTIGATOR_178234] . 
The patient will undergo the following procedures/assessments: 
• Study drug administration. 
• Laboratory assessments, inc luding: 
o Chemistry , 
o Hematology.  
• Vital signs including pulse rate, systolic and diastolic blood pressure after at least [ADDRESS_209451] in semi-supi[INVESTIGATOR_2547], respi[INVESTIGATOR_12876]). 
• Body weight via scale measurement, to be done prior to study drug administration. 
• A dedicated physical examination with focus to monitoring signs and symptoms of edema (see Section [IP_ADDRESS] for details); results of this  PE will be inserted in source 
data and in the relevant pages of eCRF . 
• 12-Lead ECG ([ADDRESS_209452] dose), in triplicate. 
• CT scan may be performed as per standard local practice. Exact time point for CT scan will depend on the investigator’s standard plan at e ach site  (see Section 7.2.7). 
• Adverse Events, procedures, and hospi[INVESTIGATOR_178235].  
• Administration and completion of  
o FACIT questionnaires (includes all [ADDRESS_209453]-G, 12- item A/CS domain and FACIT -F fatigue domain),  
o Hunger Assessment questionnaire,  
Questionnaires will be administered in the order presented here and administered from  [ADDRESS_209454] study drug administration. 
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 57 of 110 
CONFIDENTIAL   
 
• Check and record Concomitant medications (not including NSCLC treatment 
regimen) .  
• NSCLC treatment regimen and any dose adjustments, as and if applicable. 
• New study kit will be dispensed, and patient will retur n wallet card from previous 
visit; compliance will be checked . 
• The patient will also be reminded about the prohibited concomitant medications (see Section 5.13.2 for details ). 
• Patient will also be reminded to come back to clinical site in 3 weeks for next visit and be reminded to arrive at the hospi[INVESTIGATOR_178234]. 
6.1.8  Visit 8 (Day 127+3) – Week 18  
The patient will return to the trial site on Visit 8, at Day 127 (+3), approximately 3 weeks after Visit 7. Patient will arrive at the hospi[INVESTIGATOR_178234] . 
The patient will undergo the following procedures/assessments: 
• Study drug administration. 
• Laboratory assessments, including: 
o Chemistry , 
o Hematology.  
• Vital signs including pulse rate, systolic and diastolic blood pressure after at least [ADDRESS_209455] in semi-supi[INVESTIGATOR_2547], respi[INVESTIGATOR_12876]). 
• Body weight via scale measurement, to be done prior to study drug administration. 
• A dedicated physical examination with focus to monitoring signs and symptoms of 
edema (see Section [IP_ADDRESS] for details); results of this  PE will be inserted in source 
data and in the relevant pages of eCRF . 
• 12-Lead ECG ([ADDRESS_209456] dose), in triplicate. 
• CT scan may be performed as per standard local practice. Exact time point for CT scan will depend on the investigator’s standard plan at e ach site  (see Section 7.2.7). 
• Adverse Events, procedures, and hospi[INVESTIGATOR_178235].  
• Administration and completion of  
o FACIT questionnaires (includes all [ADDRESS_209457]-G, 12- item A/CS domain and FACIT -F fatigue domain),  
o Hunger Assessment questionnaire.  
Questionnaires will be administered in the order presented here and administered from  [ADDRESS_209458] study drug administration. 
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 58 of 110 
CONFIDENTIAL   
 
• Check and record Concomitant medications (not including NSCLC treatment 
regimen) . 
• NSCLC treatment regimen and any dose adjustments, as and if applicable. 
• New study kit will be dispensed, and patient will return  wallet card from previous 
visit; compliance will be checked . 
• The patient will also be reminded about the prohibited concomitant medications (see 
Section 5.13.2 for details ). 
• Patient will also be reminded to come back to clinical site in 3 weeks for next visit and be reminded to arrive at the hospi[INVESTIGATOR_178234]. 
6.1.9  Visit 9 (Day 148+3): Week 21  
The patient will return to the trial site on Visit 9, at Day 148 (+3), approximately 3 weeks after Visit 8. Patient will arrive at the hospi[INVESTIGATOR_178234] . 
The patient will undergo the following procedures/assessments: 
• Study drug admini stration , 
• Laboratory assessments, including:  
o Chemistry , 
o Hematology.  
• Vital signs including pulse rate, systolic and diastolic blood pressure after at least [ADDRESS_209459] in semi-supi[INVESTIGATOR_2547], respi[INVESTIGATOR_12876]). 
• Body weight via scale measurement, to be done prior to study drug administration. 
• A dedicated physical examination with focus to monitoring signs and symptoms of 
edema (see Section [IP_ADDRESS] for details); Results of this PE will be inserted in source 
data and in the relevant pages of eCRF . 
• 12-Lead ECG ([ADDRESS_209460] dose), in triplicate. 
• CT scan may be performed as per standard local practice. Exact time point for CT 
scan will depend on the investigator’s standard plan at each site (see Section 7.2.7). 
• Adverse Events, procedures, and hospi[INVESTIGATOR_178235].  
• Administration and completion of  
o FACIT questionnaires (includes all [ADDRESS_209461]-G, 12- item A/CS domain and FACIT -F fatigue domain),  
o Hunger Assessment questionnaire.  
Questionnaires will be administered in the order presented here and administe red from [ADDRESS_209462] study drug administration. 
• Check and record Concomitant medications (not including NSCLC treatment 
regimen) .  
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 59 of 110 
CONFIDENTIAL   
 
• NSCLC treatment regimen and any dose adjustments, as and if applicable. 
• New study kit will be dispensed, and patient will return wallet card from previous 
visit; compliance will be checked . 
• The patient will also be reminded about the prohibited concomitant medications (see 
Section 5.13.2 for details ). 
• Patient will also be reminded to come back to clinical site in 3 weeks for next visit and be reminded to arrive at the hospi[INVESTIGATOR_178234]. 
6.1.10  Visit 10 (Day 169+3): Week 24  
The patient will retu rn to the trial site on Visit 10, at Day 169 (+3), approximately 3 
weeks after Visit 9. Patient will arrive at the hospi[INVESTIGATOR_178234] . 
The patient will undergo the following procedures/assessments: 
• Patient will return wallet card from previous visit; compliance will be checked.  
• Study drug administration ( last dose). 
• Laboratory assessments, including:  
o Chemistry , 
o Hematology,  
o HbA1c Assessment . 
• Urine pregnancy test for females of childbearing potential . 
• Urinalysis under fasting status. 
• Vital signs including pulse rate, systolic and diastolic blood pressure after at least [ADDRESS_209463] in semi-supi[INVESTIGATOR_2547], respi[INVESTIGATOR_12876]). 
• Body weight via scale measurement, to be done prior to study drug administration. 
• A dedicated physical examination with focus to monitoring signs and symptoms of edema (see Section [IP_ADDRESS] for details); Results of this PE will be inserted in so urce 
data and in the relevant pages of eCRF . 
• 12-Lead ECG ([ADDRESS_209464] dose), in triplicate. 
• CT scan may be performed as per standard local practice. Exact time point for CT 
scan will depend on the investigator’s standard plan at each site (see Section 7.2.7). 
• Adverse Events, procedures, and hospi[INVESTIGATOR_178235].  
• Administration and completion of  
o FACIT questionnaires (includes all [ADDRESS_209465]-G, 12- item A/CS domain and FACIT -F fatigue domain),  
o Hunger Assessment questionnaire.  
ANAM -17-21  
Final (v5.0 )/[ADDRESS_209466] study drug administration. 
• Check and record Concomitant medications (not including NSCLC treatment 
regimen) .  
• NSCLC treatment regimen and any dose adjustments, as and if applicable. 
• Patient will also be reminded that will be contact[CONTACT_178277] -up visit 
in two weeks. 
6.1.11  Visit 11 (Follow -up visit): Week 26   
A follow -up visit , at Day 183 (+3), approximately 2 weeks after Visit 10 will be 
conducted over the telephone.  
The patient will undergo the following procedures/assessments: 
• Patient will be inquired for safety; information related to AEs, procedures, and 
hospi[INVESTIGATOR_602] ’ assessment will be collected over telephone.  
6.2 Definition of study Completion 
A patient will be defined as having “completed” the study when the patient completes Visit 11. Termination of the study before performing Visit [ADDRESS_209467] patient’s last visit.  
6.3 Premature Discontinuation of Study Drug 
Patients may withdraw their consent and discontinue the study treatm ent at any time. 
Every effort should be made to encourage patients to return for scheduled visits to 
undergo study procedures even if they discontinue study drug. Patients who prematurely discontinue will be classified as follows (only one category may be selected):  
1. An AE occurs that, in the opi[INVESTIGATOR_689], makes it unsafe for the patient to continue in the study. 
2. The patient is lost to follow -up. 
3. The patient dies.  
4. The patient withdraws consent. 
5. The Investigator, for any reason, terminates the entire study, or terminates the study for that patient; or the attending physician requests that the patient be withdrawn for any medical reason.  
6. The Sponsor or the Regulatory Authorities or the Ethics Committee(s), for any reason, terminates the entire study, or terminates the study for this trial site or this particular patient.  
If a patient is discontinued from the study after treatment with the investigational medicinal product, the Investigator must try his/her best to contact [CONTACT_178278] 9 (64+3) visit assessments in view of completing the study safety assessment by [CONTACT_178279]. Every effort will be made to collect data from the protocol- specified assessments; patients will 
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 61 of 110 
CONFIDENTIAL   
 
be asked to continue to participate in the study and complete planned visits up to the end 
of the treatment period (Week 24) even if they have permanently discontinued treatment with anamorelin/placebo (“retrieved dropout” approach). 
Patients discontinued after randomization will not be replaced. 
6.[ADDRESS_209468] treatment and throughout the duration of the study. As per National Institute on 
Alcohol Abuse and Alcoholism (NIAAA), in the [LOCATION_002], one "standard" drink 
contains roughly 14 grams of pure alcohol, which is found in: a) 12 ounces (~ 360 ml) of 
regular beer, which is usually about 5% alcohol; b) 5 ounces (~ 150 ml) of wine, which is 
typi[INVESTIGATOR_24671] 12% alcohol; c) 1.5 ounces (~ 50 ml) of distilled spi[INVESTIGATOR_2120], which is about 
40% alcohol. 
Exces sive a lcohol use is according to Substance Abuse and Mental Health Services 
Administration (SAMHSA) is a binge drinking on [ADDRESS_209469] month. 
Binge drinking is ≥ 5 drinks for males or ≥ 4 drinks for females on the same occasion 
(i.e., at the  same time or within a couple of hours of each other) on at least [ADDRESS_209470] month.  
There are no restrictions on exercise or activity.  
ANAM -17-21  
Final (v5.0 )/[ADDRESS_209471] (total domain score 
and the 4- item Anorexia Concerns S ubscale derived from the FAACT), as well as 
additional patient -reported outcome assessments including the FACIT -F, Hunger 
Assessment Scale, PGIS and PGIC  questionnaires for body weight , anorexia and overall 
conditions.  
All questionnaires  will be provided to the sites and will be completed by [CONTACT_178280]. Every effort should be made to have the patient complete the 
questionnaires alone. If they cannot physically complete them by [CONTACT_1029], then site 
personnel may read the questions to the patients and record their answers. Patient caregivers should not influence/contribute to patient responses.  
These instruments will be provided in appropriate validated translations and will be 
completed by [CONTACT_178281]. 
The PRO data will be collected by [CONTACT_178282], the data will be 
automatically tr ansferred and the sum score of the different questionnaires used for 
screening and randomization purposes will be displayed on the device. 
Site personnel should ensure all questions were answered and that the intended answers 
were clearly marked. The site personnel should ask the patient to complete any missed questions and to clarify any unclear answers. If a patient is unable to complete the questions, the reason must be documented in the source documentation and in the eCRF. The order of the questionnair es to be completed at each visit is specified within the study 
flow chart . 
7.1.1  Assessment of Body Weight  
Data from literature [ Patel -2013] and post -hoc analyses of the previous Phase [ADDRESS_209472] that increases in body weight of a magnitude of ≥ 5% from baseline are relevant, associated with corresponding improvemen ts in anorexia -related 
concerns proximal to the weight loss, and are noticeable and clinically meaningful to patients.  
Body weight will be measured in kg at each visit (for details see study flow chart ). 
Measurements will be performed by a Sponsor -trained and certified healthcare 
professional.  Body weight will be assessed for the purpose of primary, secondary and exploratory 
efficacy endpoints, as indicated in Section 3. 
Calibrated and validated scale will be used at every visit, including screening visit (Visit 
1). Scales will be used on hard flooring, such as tile, wood, or cement for accuracy of 
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 63 of 110 
CONFIDENTIAL   
 
meas urement. Sites will be instructed to weigh the participants at approximately the same 
time of the day every visit, on empty stomach (in the morning, before breakfast). Study 
participants will be instructed to remove shoes and clothing for accurate weight 
measurement. Patients will be weighed wearing only a hospi[INVESTIGATOR_178236], if desired, underwear only. Sponsor will make sure the same scale is used at each site. 
7.1.2  Assessment of anorexia symptoms and other patient reported outcomes  
In this s tudy, three different types of patient -reported outcome measures will be 
administered to patients, following instructions provided in study flow  chart. These 
questionnaires are listed below , and additional details are provided in each of the 
following sections: 
• FACIT measurements , 
• PGI System ,  
• Hunger Assessment Scale. 
7.1.3  Patient Reported Outcome  
[IP_ADDRESS]  FACIT measurements (Functional Assessment of Chronic Illness Therapy)  
This is a collection of questionnaires targeted to the management of chronic illness  
[FACIT.org ] and includes (please see APPENDIX 4 for details):  
• FAACT -A/CS (Functional Assessment Anorexia Cachexia Therapy): this domain 
is a 12 -item measure of patients’ perceptions of anorexia/cachexia symptoms and 
concerns [ Ribaudo-2001]. From this questionnaire the 5- item section referring to 
anorexia symptoms will be used to assess primary efficacy endpoint. 
• FACIT -F (Fatigue): this domain is a 13 -item measure specifically to address the 
physical and functional consequences of fatigue [ FACIT.org ]. 
• FACT -G (Functional Assessment Cancer Therapy - General Version);  this is a 27 -
item compi[INVESTIGATOR_178237]: Physical Well -Being, Social /Family Well-Being, Emotional Well-Being, and Functional 
Well -Being.  For this study, patients will be administered all four domains. 
Regarding FACIT questionnaires, 5-item Anorexia Symptom Subs cale and a [ADDRESS_209473] A/CS 
domain, whereby [CONTACT_178283] a qualitative study in NSCLC patients and a retrospective psychometric evaluation using data from the two previous Phase 3 trials  with anamorelin [ Gelhorn-2016].  
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 64 of 110 
CONFIDENTIAL   
 
In terms of scoring the questionnaires, all negatively worded item responses are reverse 
coded and summed in accordance with the recommendations of the FACIT 
Administration and Scoring Guidelines so that higher scores indicate lower levels of 
QoL/symptom burden (see APPENDIX 5  for details).  
Definitions of the different scores from these questionnaires, are as follows: 
• FACT -G total score:  obtained by [CONTACT_178284] -Being, Social/Family 
Well -Being, Emotional Well-Being, and Functional Well- Being  subscale scores of 
the FACT -G; the range of possible scores is 0-108. 
• FAACT total score: obtained by [CONTACT_104150]-G and the A/CS domain; the 
range of possible scores is 0-156. 
• FAACT TOI: obtained by [CONTACT_178285] -Being and Functional Well-
Being subscale scores of the FACT -G plus the A/CS domain; the range of possible 
scores is 0 -104.  
• FAACT A/CS Domain: obtained by [CONTACT_10621] 12- items of the A/CS domain; 
the range of possible scores is 0-48,  
• 5-item A norexia Symptom S ubscale: obtained by [CONTACT_10621] 5 anorexia 
symptom items derived from the A/CS domain (i.e., “good appetite,” “interest in food drops,” “food tastes unpleasant,” “get full quickly,” and “difficulty eating rich/heavy foods ”); the range of possible scores is 0 -20 
• 4-item Anorexia Concerns S ubscale: obtained by [CONTACT_10621] 4 anorexia 
concern items derived from the A/CS domain (i.e., “ amount I eat sufficient,” 
“worried about weight,” “concerned about thinness,” and “pressured to eat ”); the 
range of possible scores is 0-16,  
• FACIT -F Fatigue Domain: obtained by [CONTACT_10621] 13- items of the fatigue 
domain; the range of possible scores is 0-52,  
• FACIT -F TOI: obtained by [CONTACT_178285]-Being and Functional 
Well -Being subscale scores of the FACT -G plus the fatigue domain; the range of 
possible scores is 0 -108.  
[IP_ADDRESS]  PGI (Patient Global Impression) System  
This is a collection of two questionnaires (please see APPENDIX 6  for details):  
• PGIS (Patient Global Impression of Severity ): This is a two -items PRO, each 
with a 4-point Likert -type response scale, one ranging from ‘‘do not have” 
symptoms to “severe” symptoms related to appetite/eating , and the other one 
ranging from ‘‘ have not had” concerns to “have had severe” concerns related to 
weight. 
 
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 65 of 110 
CONFIDENTIAL   
 
• PGIC (Patient Global Impression of Change):  This is a three- item PRO  (overall, 
anorexia and body weight) , each with a 7 -point Likert-type response scale ranging 
from ‘‘very much worse’’ to ‘‘very much improved’’ appetite/eating -related 
symptoms and  overall condition.  
[IP_ADDRESS]  HAS (Hunger Assessment Scale)  
This questionnaire consists of two questions and each question can be ranked from 0 (not 
at all) to 4 (very much) scale (please see APPENDIX 7  for details).  
 
7.2 Safety Assessments  
7.2.1  Demographic/Medical History  
A complete medical history will be recorded at the Screening Visit and will include 
evaluations for past or present conditions. Demographic information (including age, gender, race and ethnicity) and information on histological  or
 cytological tumor type, 
genotype and treatment will also be collected at the Screening Visit.  
7.2.2  Physical examination  
A complete physical examination will be performed by [CONTACT_178286], as 
applicable at Visit 1 (Screening Visit) and at each visit during the treatment period [Visit 
2 (Week 1), Visit 3 (Week 3), Visit 4 (Week 6), Visit 5 (Week 9), Visit 6 (Week 12), 
Visit 7 (Week 15), Visit 8 (Week 18), Visit 9 (Week 21), and Visit 10 (Week 24)]. This evaluation will include an examination of general appearance, head, eyes, ears, nose, 
throat, skin, neck, lungs, cardiovascular, breast, lymph nodes, abdomen, m usculoskeletal 
and neurological. For details see study flow charts. 
Information about the physical examinations will be recorded in the source 
documentation at the site and any abnormalities at screening will be recorded in the 
eCRF. After signing the informed consent, any new or worsening of existing pathological findings noted since previous examination performed under the present protocol should be reported on the Adverse Event eCRF form. 
[IP_ADDRESS]  Monitoring Signs and symptoms of edema  
Since excess in body water may contribute to a change in body weight and confound the 
primary efficacy analysis, all patients will be monitored for the signs and symptoms of 
edema during the study. Signs and symptoms of edema will be recorded in patient charts 
at each study visit. For scheduling details see study flow chart. 
A dedicated PE aiming to monitor signs and symptoms of edema should be performed on 
limbs, abdominal and thoracic landmarks. Edema should be evaluated for pi[INVESTIGATOR_22940], 
tenderness to palpation (by [CONTACT_178287]), and skin temperature, color, and texture changes . 
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 66 of 110 
CONFIDENTIAL   
 
Limbs Edema: 
PE should focus on dorsum of the foot, all foot including ankle, the medial malleolus, and 
the bony portion of the tibia. In general, PE should focus on the assessment of edema 
involving all part of limb distal to middle point (knee, elbow), all limb involved from proximal joint (hip, elbow), and all limbs. 
Abdominal and Thoracic Edema 
PE should focus on visual and palpation assessment of the abdominal area, while for the 
evaluation of thoracic edema will be complemented by [CONTACT_162014].  
Data of patients with fluid retention will be handled as described in Section 9.4.1. 
7.2.3  Vital signs  
Vital signs will be measured at Visit 1 (Screening Visit) and at each visit during the 
treatment period [Baseline Visit 2 (Week 1), Visit 3 (Week 3), Visit 4 (Week 6), Visit 5 (Week 9), Visit 6 (Week 12), Visit 7 (Week 15), Visit 8 (Week 18), Visit 9 (Week 21), 
and Visit 10 (Week 24)], for details see study flow charts. 
Vital sign assessments include body temperature, pulse rate, blood pressure (systolic and 
diastolic), and respi[INVESTIGATOR_697]. Pulse rate, systolic and diastolic blood pressure will be measured after the patient has been resting in the semi -supi[INVESTIGATOR_21683] 5 
minutes.  
7.2.4  Height and BMI  
Height will be measured in cm at the Screening Visit (Day - 7 to - 1, Week -1), and BMI 
will also be calculated and recorded.  
7.2.5  12-lead ECG  
12-lead ECGs will be conducted in triplicate at each visit Screening Visit, Visit 2 (Week 
1), Visit 3 (Week 3), Visit 4 (Week 6), Visit 5 (Week 9), Visit 6 (Week 12), Visit 7 
(Week 15), Visit 8 (Week 18), Visit 9 (Week 21), and Visit 10 (Week 24). These [ADDRESS_209474] blind to the study treatment. Any new or worsening ECG abnormalities assessed to be clinically significant by [CONTACT_178288]. 
ECG will be recorded in triplicate at 1 hour (±5 minutes) post dose at each visit to align 
with occurrence of C
max, with the excep tion of Screening Visit ( where ECG will be taken 
only pre-dose) and Visit 2, Day 1, where ECG will be taken also at pre-dose. 
7.2.[ADDRESS_209475] be processed and 
shipped will be provided to the Investigator in the relevant laboratory manual. 
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 67 of 110 
CONFIDENTIAL   
 
HbA 1c will be per formed at Visit 1 (Screening visit), Visit 6 (Week 12), and Visit 10 
(Week 24) visits.  
[IP_ADDRESS]  Hematology  
The hematology assessments will include CBC with differential count and will be 
performed at every visit: Screening Visit, Visit 2 (Week 1), Visit 3 (Week 3), Visit 4 (Week 6), Visit 5 (Week 9), Visit 6 (Week 12), Visit 7 (Week 15), Visit 8 (Week 18), Visit 9 (Week 21), and Visit 10 (Week 24). 
[IP_ADDRESS]  Blood Chemistry  
Blood Chemistry will include sodium, potassium, chloride, calcium, total protein, 
albumin and pre -albumin, AST (SGOT), alkaline phosphatase (ALP), ALT (SGPT), total 
bilirubin, creatinine, C -reactive protein and glucose. These will be performed at every 
visit in fasting state: Screening Visit, Visit 2 (Week 1), Visit 3 (Week 3), Visit 4 (Week 6), Visit 5 (Week 9), Visit 6 (Week 12), Visit 7 (Week 15), Visit 8 (Week 18), Visit 9 (Week 21), and Visit 10 (Week 24). 
[IP_ADDRESS]  Urinalysis  
Urinalysis will be performed at Visit 1 (Screening), Visit 5 (Week 9), and Visit 10 (Week 
24). Urinalysis will be performed pre -dose and under fasting conditions and will include 
protein, glucose, WBC, erythrocytes, and bacteria. 
[IP_ADDRESS]  Pregnancy Screen  
Urine pregnancy testing for women of childbearing potential only will be performed at 
Screening visit (Week - 1), Visit 2 (Week 1), Visit 5  (Week 9), and Visit 10 (Week 24). 
7.2.[ADDRESS_209476] 1.1 [ Eisenhauer-2009] and will be recorded in the eCRF. 
  
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 68 of 110 
CONFIDENTIAL   
 
8 ADVERSE EVENTS 
AE recording will begin at the time the informed consent form is signed. Thereafter, AEs 
will be ascertained by [CONTACT_178289]/she has been since the last visit. 
8.1 Definition of Adverse Events  
Adverse Event (AE)  
As defined by [CONTACT_178290] [ ICH-2002]  an 
Adverse Event (AE) is:  
Any untoward medical occurrence in a patient or clinical investigation subject 
administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. 
Within the scope of this study, such untoward medical occurrences would be considered 
as “AEs” even if the subject was not administered the study drugs but had already signed 
the Informed Consent Form. 
AEs include the following types of occurrences: 
− Suspected adverse drug reactions 
− Other medical experiences, regardless of their relationship to the study drugs, 
such as injury, surgery, accidents, increased severity of pre -existing symptoms, 
apparently unrelated illnesses, and significant abnormalities in clinical laboratory values, physiological testing, or physical examination findings 
− Reactions from drug overdose, abuse, withdrawal, hypersensitivity, or toxicity. 
Planned surgical interventions or planned hospi[INVESTIGATOR_178238] (study procedures, chemotherapy cycles, etc.) should not be considered (serious) AEs.  
Serious Adverse Event (SAE) 
A serious adverse event is any event that suggests a significant hazard, contraindication, 
side effect, or precaution, whether or not it is considered to be associated with the study 
product. A SAE is an AE that meets any of the following criteria: 
− Results in death. This includes any death that occurs during the conduct of a 
clinical study, including deaths that appear to be completely unrelated to the study drugs (e.g., car accident). 
− Is life -threatening. This includes any AE during which the subject is, in the view 
of the Investigator, at immediate risk of death from the event as it occurs. This definition does not include events that may have caused death if they had occurred in a more severe form.  
− Requires inpatient hospi[INVESTIGATOR_103296]  
− Results in persistent or significant disability or incapacity  
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 69 of 110 
CONFIDENTIAL   
 
− Is a congenital anomaly or birth defect 
− Other medical events that based upon appropriate medical judgment are thought 
to jeopardize the patient and/or require medical or sur gical intervention to prevent 
one of the outcomes defining a SAE. 
Unexpected Adverse Event 
An Unexpected Adverse Event is any experience not previously reported (in nature, 
severity or incidence) in the current Investigator’s Brochure . 
 
Pre-existing Condition 
A pre -existing condition is one that is present at the start of the study. A pre -existing 
condition should be recorded as an adverse event if the frequency, intensity, or the 
character of the condition worsens during the study period based on patient’s clinical 
evaluation . 
8.1.[ADDRESS_209477] be made by [CONTACT_178291] 
(see Section  [IP_ADDRESS] Severity ), and its relationship (see Section  [IP_ADDRESS] Relationship to 
Investigational Medicin al Product). 
[IP_ADDRESS]  Severity  
The severity of an AE will be rated by [CONTACT_178292] (CTCAE) (for details please refer to the integral document Terminology Criteria for Adverse Events [CTCAE -2017]; U SA Department of Health and Human Services, National Institutes of 
Health, National Cancer Institute), as summariz ed below:  
Severity of AE according to CTC Grading Scale and related Guideline 
Grade 1  Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated; 
Grade 2  Moderate; minimal, local or noninvasive intervention indicated; limiting 
age-appropriate instrumental Activities of Daily Living (ADL)*;  
Grade 3  Severe or medically significant but not immediately life -threatening; 
hospi[INVESTIGATOR_3111]; disabling; limiting self -care A DL**;  
Grade 4  Life-threatening consequences; urgent intervention indicated; 
Grade 5  Death related to AE.  
(*) Instrumental ADL refer to preparing meals, shoppi[INVESTIGATOR_3112], using the telephone, managing 
money, etc.  
(**) Self -care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not 
bedridden. 
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 70 of 110 
CONFIDENTIAL   
 
[IP_ADDRESS]  Relationship to Investigational Medicinal Product  
For this trial, an AE cause and effect relationship to the study drug will be classified by 
[CONTACT_178293].  
Scale  Definition  
Definitely 
Related  The evidence is compelling that the study drug caused the adverse 
event. There is a clear temporal relationship of the event to the study drug; the event is consistent with a known pattern of drug (or drug class) effects; the event cannot be explained by [CONTACT_9153]; the event diminished upon cessation of study drug exposure or reduction in dose; the event worsened or recurred upon unintentional re-exposure to the study drug (intentional rechallenge for 
the purpose of assigning causality should not be performed).  
Probably 
Related  It is more likely that the event is due to the study drug than due to other 
aetiologies, an alternative explanation is unlikely. There is a reasonable temporal relationship of the event to the study drug; the event may be consistent with a known pattern of drug (or drug class) effects; the drug seems more likely than other aetiologies to cause the effect; the event 
diminished upon cessation of study drug exposure or reduction in dose.  
Possibly 
Related  It is equally likely that the event is due to the study drug as it is due to 
other aetiologies. There is a reasonable temporal relationship of the event to the study drug; follows a known or expected response pattern of the suspected drug but could also have been easily produced by a 
number of other aetiologies.  
Unlikely 
related  
 It is more likely that the event is due to other aetiologies than due to the 
study drug. The event could have been reasonably related to patient's underlying diseases or concomitant tre atments and/or the temporal 
relationship is doubtful between the study drug and the suspected adverse event.  
It the temporal relationship of the event to the study drug is reasonable, but there are important confounding factors/reasonably convincing 
altern ative explanations, causality is considered unlikely.  
Not related  The study drug almost certainly (or certainly) did not cause the event. 
Sufficient information exists to indicate that the aetiology is unrelated to the study drug, e.g., the event is more likely related to patient's underlying diseases or concomitant treatments and/or there is no temporal relationship between the study drug and the suspected adverse 
event, e.g. the event occurred before the study drug was administrated.  
Unassessable  The data are insufficient or contradictory to make a meaningful medical 
assessment.  
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 71 of 110 
CONFIDENTIAL   
 
8.1.2  Reporting Adverse Events  
AE reporting has to be in accordance with the ICH E6 Guidance on GCP and ICH E2A 
Guidance on Clinical Safety Management [ ICH-1997; ICH -1994 ]. 
During the course of the study, all AEs (including SAEs), irrespective of the relatedness  
to the study drugs, must be recorded in detail in the source records and transcribed onto the AEs  pages of the eCRF. During each monitoring visit, the Investigator and the site 
monitor will review all AEs and perform Source Data Verification (SDV). The Investigator will be responsible for ensuring that the correct information concerning all AEs is ent ered on the appropriate eCRF pages.  
In case clinically significant laboratory abnormalities are detected, the etiology of the abnormality should be identified, and the diagnosis should be recorded as an AE. Otherwise, if the etiology cannot be identified, the laboratory abnormality as such should be recorded as the AE.  
Similarly, clinically significant laboratory abnormalities detected at the screening visit (before any administration of the investigational medicinal product or additional non-investigationa l drug), if not justified by [CONTACT_178294], are to be recorded as AEs.  
The reporting period for AEs is the period starting from the time of Informed Consent signature [CONTACT_178332] 183 (+3) days post study drug administration on Day 1. 
All unresolved AEs (including SAEs) will be documented on the eCRF as “ongoing”. 
[IP_ADDRESS]  Adverse Events of Special Interest  (AESI)  
Adverse Events of Special Interest are defined as pre- specified events, under monitoring 
by [CONTACT_178295].  
In this study protocol AESIs  are considered the following:  
1. AST increase (CTCAE G ≥ 3)  
2. ALT increase (CTCAE G ≥ 3)  
3. Presyncope 
4. Syncope 
5. Ventricular arrhythmia (CTCAE G ≥ 3)  
6. Heart fai lure (CTCAE G ≥ 3)  
7. Unexplained sudden death 
8. Seizure (any CTCAE Grade)  
9. Hyperglycemia (CTCAE G ≥ 3)  
[IP_ADDRESS]  Adverse Events Associated with an Overdose  
An overdose is any dose of study treatment given to a patient  or taken by a patient  that 
exceeds the dose described in the protocol. An overdose is the accidental or intentional 
ANAM -17-21  
Final (v5.0 )/[ADDRESS_209478] (IRB)/Eth ics Committee (EC) about SAEs according to the local IRB/EC 
requirements. It is the responsibility of the Sponsor (or Sponsor’s designee) to submit applicable SAE Reports to the Competent Authorities. Reporting of suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) to the relevant IRB/EC, in accordance with the EU Clinical Trial Directive 2001/20/EC, the US Code of Federal Regulations 313.32 and ICH E6 Guidance on GCP and ICH E2A Guidance on Clinical Safety Management, will also be the responsibility of the Sponsor (or Sponsor’s designee) [ ICH-
1997; ICH -1994 ]. 
A safety contact [CONTACT_178296]. Instructions will be provided to the investigators for submission of the SAEs to the CRO. 
Any serious and unexpected AE that the Investigator or the Sponsor considers to be at 
least possibly related to study drug is subject to expedited reporting to the appropriate Health Authorities. Events for which causality is unknown/unassessable or unreported by [CONTACT_178297]. 
The procedure to unblind a patient is described in Section 5.9. 
[IP_ADDRESS]  Follow- up of Serious Adverse Events  
SAEs will be followed by [CONTACT_178298], has reached a 
stable condition in the Investigator’s opi[INVESTIGATOR_1649], or until the patient is lost to follow -up. 
When the investigational site receives any information about a serious adverse event which changes or adds further information about the initial SAE, the site will send this information within [ADDRESS_209479] on the seriousness, relatedness or expectedness of an adverse event.  
ANAM -17-21  
Final (v5.0 )/[ADDRESS_209480] be forwarded to the CRO e -mail address or sent by [CONTACT_166740] (see 
Section General Information ). After check of consistency, designated personnel at the 
CRO will then forward the information to the Sponsor within 24 hours of becoming aware of the pregnancy. Even though pregnancy is not considered as SAE itself, pregnancy has to be reported within the timelines as defined for SAE.  
Pregnant patients will be followed by [CONTACT_178299] / Sponsor until the fetus / newborn is delivered. At the study end and database closure, reports of Pregnancy Outcome will be sent by [CONTACT_178300]. The subject’s primary care physician (or obstetrician) will be requested by [CONTACT_178301]. If pregnancy occurs while the patient is on study treatment or up to [ADDRESS_209481] will be discontinued from the study. 
If a female partner of a male patient becomes pregnant during the male patient’s 
participation in this study and gives consent to collect information, the investigator must fill the pregnancy form and forward it to the CRO. The pregnancy must be followed for the final pregnancy outcome and the development of the child after birth. The pregnancy outcome form must be filled in by [CONTACT_178302]. 
 
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 74 of 110 
CONFIDENTIAL   
 
9 STATISTICS  
This section summarizes the statistical principles and methods planned to analyze the 
data for the ANAM -17-21 clinical study. The reference document is the ICH Topic 
E9(R1) Statistical Principles for Clinical Trials: Note for Guidance on Statistical 
Principles in Clinical Trials [ ICH-1998].  
Further details of the statistical analyses and data presentations to be used in reporting the study will be provided in the Statistical Analysis Plan (SAP), which will be finalized prior to breaking the blind. Changes from analyses planned in this protocol will be documented in the SAP and/or study report. The database will be locked after all queries are resolved, and a blinded review of data is performed, and decisions made about study 
populations and handling of unused or missing data. 
9.1 Strati fication factors  
The stratification aims to balance investigational treatment within group of prognostic 
factors.  
Central randomization will be stratified by [CONTACT_178255]- cancer treatment (first 
line vs second line vs third line), by [CONTACT_178256]-cancer therapy (immunotherapy vs non -
immunotherapy) and by [CONTACT_178257] 5- item Anorexia Symptom S ubscale (≤10 vs 
>10).  
9.2 Sample Size Determination  
At the time the trial was initiated, the primary endpoint was the Composite Clinical Response (CCR) r ate. The sample size was determined based on results obtained on 
patients participating to the previous trials (HT -ANAM -301 and HT -ANAM -302). A 
logistic regression of the CCR on the randomized treatment with a sample size of 316 patients (158 patients per arm) would achieve 90% power at a [ADDRESS_209482] corresponds to an odds ratio of 3.083. (SAS
® - PROC POWER)  
From the v4.A , the protocol has been amended in order to change from a primary 
efficacy endpoint based on the CCR at week 9 to two co -primary efficacy endpoints: the 
duration of treatment benefit in weight at Week 12, and duration of treatment benefit in 5-item Anorexia Symptom S ubscale at  Week 12.  
Adequate power was confirmed by [CONTACT_178303] -primary endpoints (joint 
power greater than 90%). However, during the course of the study an error was discovered in the algorithm used to determine the statistical power for the evaluation  of 
the duration of treatment benefit from baseline to Week 12 for body weight and anorexia 
(5-IASS) co-primary endpoints. N ew simulations correcting for the programming error 
were performed and these results confirmed high power (over 98%) for the weight -based 
co-primary endpoint but showed low power for the 5- IASS co -primary endpoint 
(between  60 and 70%).  
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 75 of 110 
CONFIDENTIAL   
 
Power for the new co -primary endpoints (mean change in body weight and mean change 
in 5- IASS) with the fixed sample size of 158 patients per arm was computed by [CONTACT_178304]. Power for mean change in body weight was showed to be close to 100%, 
while power for mean change in 5- IASS was showed to range between 78% and 87%, so 
leading to a joint power for the two co- primary endpoints of at least 7 8%. 
9.3 Definition of Study Populations for Analysis (Analysis Set)  
Study populations are defined as follows: 
Safety Set  
The Safety Set includes all patients who receive any study drug and will be analyzed as 
per actual treatment.  
ITT Set  
The Intent -to-Treat (ITT) Set includes all randomized patients and will be analyzed as per 
planned treatment.  
Full Analysis Set  
The Full Analysis Set (FAS) includes all randomized patients who take at least one dose of trial medication, and for which post randomization data are collected. The definition may be updated at the time of the blind review of the data at the end of the trial.  
Per-Protocol (PP) Set  
The Per -Protocol Set is the subset of the randomized patients who do not have major 
protocol violations.    
9.4 Statistical A nalysis  
9.4.1  Missing Data  
A detailed presentation of missing data will be produced, indicating their amount and 
incidence by [CONTACT_3148], visit and reason (For instance: visit not done, assessment not done).  
Every effort will be made to collect data from the pro tocol- specified assessments; 
patients will be asked to continue to participate in the study and complete planned visits 
up to the end of the treatment period (Week 24) even if they have permanently discontinued treatment with anamorelin/placebo (“retrieved  drop- out” approach). Reason 
for treatment discontinuation will be precisely collected in the CRF and will be used to investigate possible unexpected patterns of missing data and for the imputation itself.  
However, due to the nature of the patients’ underlying disease, a non-ignorable amount of missing data is expected in this trial. To minimize the risk of bias in the analysis, ad hoc rules for single/multiple imputation will be adopted. The multiple imputation (MI) method for missing data, is  described in  the literature [
Ratitch  -2014;  Ratitch  -2013].  
The missing data of the variables being part of the primary efficacy endpoints (weight, 5-item Anorexia Symptom Subscale score) and the secondary/explo ratory  efficacy 
ANAM -17-21  
Final (v5.0 )/[ADDRESS_209483] ing to the ICH  E9(R1) guideline [ ICH-1998] , 
death is considered as an intercurrent event, after which no value is measurable. In order 
to measure the treatment effect for these patients, the “while alive” strategy will be used. Therefore, only values collected before death for patients dying before the endpoint will 
be used for the analyses .  
9.4.2  Multiplicity  
The primary and the secondary efficacy endpoints will be tested using a hierarchy for testing in order to control type I error rate.  The order of testing will be as follows: the co -primary efficacy endpoints related to the 
mean change in weight (H
0w) and related to the mean change in 5- item Anorexia 
Symptom Subscale  (H 0a), then the secondary efficacy endpoints: the duration of benefit in 
weight (≥0) (H 0d0w), the duration of benefit in weight (≥ to a predefined threshold) 
(H0dtw), the duration of benefit in 5- IASS (≥ 0) (H 0d0a), the duration of benefit in 5- IASS 
(≥ to a predefined threshold) (H 0dta), then the mean change in FAACT 12- item A/CS 
domain score (H 0mF), in FACIT -F (H 0mFF) and in FAACT total score (H 0mFT) . Each of 
these tests will be done sequentially at the level of 0.[ADDRESS_209484] component (anamorelin) superior to the placebo, both co-primary endpoints must be significant, meaning that both H
0w and H 0a must be rejected  simultaneously. Additional details are 
presented in Section 9.4.5.  
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 77 of 110 
CONFIDENTIAL   
 
9.4.3  Subgroups  
Subgroup analysis will be conducted for the following subgroups,  as far as adequate 
number of patients in subgroups is confirmed at the BDRM : 
• Age (≤ 65 years or > 65 years)  
• Gender  
• Geographic region  
• Systemic anti- cancer treatment line (first line vs second line vs third line) – 
stratification factor  
• Cancer treatment (immunotherapy vs no immunotherapy) – stratification factor  
• The 5 -item Anorexia Symptom Subs cale (≤10 vs >10) – strat ification factor  
• Patients who completed 24 weeks treatment 
• Patients with at least one treatment emergent adverse event  with preferred term 
belonging to fluid retention related (codified under PT ‘Fluid retention’, ‘Ascites’, 
‘Pleural effusion’, ‘Oedema per ipheral’, ‘Oedema’, a specific review of the LLT 
will be done during the BDRM to confirm if adverse events are possibly impacting the weight measurement) and/or patients with signs of edema as defined in Section 
[IP_ADDRESS]. 
• Race and Ethnicity  
9.4.[ADDRESS_209485] listing for all data will be provided.  
9.4.5  Efficacy Analysis  
The efficacy analysis will be performed on the ITT population. Some supportive analyses 
of the primary efficacy endpoints will be performed on different populations (PP set and FAS set) . 
The analys es will be produced after the imputation of the missing data.  The imputed 
datasets used for the primary endpoint analysis will be used for the analyses of the secondary and exploratory endpoints. When the data will be considered as missing (see 
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 78 of 110 
CONFIDENTIAL   
 
Section 9.4.1), the imputation of the values will be done  at the level of the visit for the 
raw values (for instance weight) . Then, the  primary endpoints (for instance mean change 
in weight)  and the secondary endpoints will be derived from the imput ed raw values  and 
not directly imputed. 
Individual subject listing for all data observed (not imputed) will be provided.   
[IP_ADDRESS]  Primary Efficacy Analysis 
The primary efficacy endpoints are defined in Section 3.1.1 
• Mean change in body weight from baseline over 12 Week s.  
• Mean change in 5- item Anorexia Symptom S ubscale form baseline over [ADDRESS_209486] co -primary endpoint of mean change  in body 
weight (H
0w) and the corresponding alternative hypothesis (H 1w) are defined as:  
H0w: MW a = MW p 
H1w: MW a ≠ MW p 
Where MW a is the mean change in body weight for the anamorelin arm and MW p is the 
mean change in body weight for the placebo arm. 
The null hypothesis concerning the second co -primary endpoint of mean change in 
patient 5-item Anorexia Symptom S ubscale (H0a) and the corresponding alternative (H 1A) 
are defined as:  
H0a: MA a = MA p 
H1a: MA a ≠ MA p 
Where MA a is the mean change  in 5-item Anorexia Symptom S ubscale score for the 
anamorelin arm and MA p is the mean change in 5- item Anorexia Symptom S ubscale 
score for the  placebo arm.  
The mean change effect will be computed as mean of the changes from baseline over [ADDRESS_209487] assessment (either Week 12 or before), and then divided by 
[CONTACT_178305] (observed or imputed) from baseline up to the time of the last assessment (either Week 12 or before, in case of death , for the analysis at W eek 12 ). 
The primary efficacy analyses will be conducted on the ITT. H
0w and H 0a will be tested 
using an ANOVA to compare the two treatment groups, at a type-I error threshold of 0.[ADDRESS_209488] error (SE) will be computed, then pooled using the Rubin rule, the pooled difference and the related p -value will be interpreted for the primary efficacy analyses. In 
addition, t he least squares (LS) -mean and 95% confidence interval will be presented per 
treatment group. 
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 79 of 110 
CONFIDENTIAL   
 
[IP_ADDRESS]  Sensitivity and supportive analys es of the primary efficacy 
endpoint s 
[IP_ADDRESS].1  Se nsitivity analys es of the primary efficacy endpoint s 
The sensitivity analyses are aimed to confirm robustness of the conclusion of the primary 
efficacy analysis but are not part of the multiplicity adjustment.  
A sensit ivity analysis regarding imputation of missing will be performed using data from 
the placebo group only (control -based imputation) for patients who do not have properly 
matched patients with complete follow -up. 
An analysis similar to the primary efficacy analysis will be also conducted after having 
imputed the values of weight obtained in presence of fluid retention (See Section 9.4.3). 
The details of the patients r egarding the fluid retention will be summarized. 
[IP_ADDRESS].2  S upp ortive analys es of the primary efficacy endpoint s 
Two analyses similar to the primary efficacy analysis will be conducted, one on the FAS 
population and another one on the PP  for each of the primary endpoints . The FAS and the 
PP are impacted by [CONTACT_178306]. The results of these analyses are expected to be similar to the one of the primary efficacy analysis. 
Primary efficacy endpoint s will be presented for all the subgroups (listed in Section  
9.4.3).  
[IP_ADDRESS]  Secondary Efficacy Analysis 
All the analyses of the secondary endpoints will be conducted on th e ITT.  
The secondary endpoints (See Section 3.1.2) will be evaluated following a hierarchal 
approach, as follows: duration of treatment benefit (≥0) in body weight  up to Week [ADDRESS_209489] secondary endpoint, then duration of treatment benefit (≥ to a predefined 
threshold) in body weight up to Week 12, duration of treatment benefit (≥0) in 5- IASS up 
to Week 12, duration of treatment benefit in 5- IASS (≥ to a prede fined threshold) up to 
Week 12, mean change in FAACT 12-item A/CS domain  score from baseline up to Week 
12, mean change in FAACT total score from baseline up to Week [ADDRESS_209490] secondary endpoint of duration of treatment 
benefit in body weight (≥0) ((H
0d0w) and the corresponding alternative hypothesis (H 1d0w) 
are defined as:  
H0d0w: D0Wa = D 0Wp 
H1d0w: D0Wa ≠ D 0Wp 
Where D 0Wa is the duration of treatment benefit in body weight (≥0) for the anamorelin 
arm and D 0Wp is the duration of treatment benefit in body weight for the placebo arm. 
H0d0W will be tested using a two -sided type -I error threshold of 0.05 only if both H 0w and 
H0a (i.e., the null hypothesis concerning the primary endpoints) are rejected. 
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 80 of 110 
CONFIDENTIAL   
 
The null hypothesis concerning the secondary endpoint of duration of treatment benefit in 
body weight (≥ to a predefined threshold) (H 0dtW) and the corresponding alternative 
(H1dtW) are defined as:  
H0dtW: DtWa = D tWp 
H1dtW: DtWa ≠ D tWp 
Where D tWa is the duration of treatment benefit in weight (≥ to a predefined threshold) 
for the anamorelin arm and D tWp is the duration of treatment benefit in weight for the 
placebo arm.  
H0dtW will be tested using a type -1 error threshold of 0.05 two sided only if H 0d0W (i.e., 
the null hypothesis concerning the first secondary endpoint) is rejected; note the latter rejection requiring the rejection of if both H
0w and H 0a. 
The following hypothesis sys tems will then be tested based on the rules above described.  
H0d0A: D0Aa = D 0Ap 
H1d0A: D0Aa ≠ D 0Ap 
Where D 0Aa is the duration of treatment benefit in 5 -item Anorexia Symptom Subscale 
(≥0) for the anamorelin arm and D 0Ap is the duration of benefit in 5 -item Anorexia 
Symptom Subscale for the placebo arm. 
H0dtA: DtAa = D tAp 
H1dtA: DtAa ≠ D tAp 
Where D tAa is the durat ion of treatment benefit in 5 -item Anorexia Symptom Subscale (≥ 
to a predefined threshold) for the anamorelin arm and D tAp is the duration of benefit in 5-
item Anorexia Symptom Subscale for the placebo arm. 
H0mf: MFa = M Fp 
H1mf: MFTa ≠ M Fp 
Where MF a is the  mean change in FAACT 12-item A/CS domain score in the anamorelin 
arm and MFT p is the mean change in FAACT 12-item A/CS domain  score in the placebo 
arm. Similar hypothesis systems are set- up for FAACT total score ( H0mFt, H1mFt) and 
FACIT -F (H0mFF, H1mFF). 
If the co -primary analysis leads to rejection of H 0w and H 0a, then the following hypothesis 
will be tested sequentially: secondary efficacy endpoint related to the duration of treatment benefit in weight (≥0) (H
0d0w), the secondary efficacy endpoint related to the 
duration of treatment benefit in weight (≥ to a predefined threshold) (H 0dtw), the 
secondary effic acy endpoint related to the duration of treatment benefit in 5- IASS (≥0) 
(H0d0A), the secondary efficacy endpoint related to the duration of treatment benefit in 5-
IASS ((≥ to a predefined threshold) (H 0dtA) and then the secondary efficacy endpoint 
related  to the mean change in FAACT 12 -item A/CS domain score (H 0mF), FACIT -F and 
FAACT total score. Each of these tests will be done sequentially at the level of 0.05 bilateral.  
ANAM -17-21  
Final (v5.0 )/[ADDRESS_209491] assessment (either week 12 or before and then divided by [CONTACT_178305] (observed or imputed) from baseline up to the time of the last assessment (either week 12 or before, in case of death).  
All the secondary endpoints (duration of treatment benefit and mean change from baseline) will be analyzed by [CONTACT_178307], and the stratification factors .  
The least squares (LS) -mean and 95% confidence interval will be presented per treatment 
group together with the LS -mean treatment effect and its 95% confidence interval. 
Statistics will be evaluated in each imputed datasets and pooled using Rubin’s method. 
[IP_ADDRESS]  Exploratory Efficacy Analysis  
All the analyses of the exploratory endpoints will be conducted on the ITT. 
The exploratory efficacy analyses are aimed to explore the effect of the anamorelin on 
different endpoints but are not part of the multiplicity adjustment, thus have no confirmatory value. The exploratory efficacy endpoints are detailed in Section 3.1.3.  
The duration of benefit and mean change from baseline endpoints will be analyzed like 
the main analysis for the primary efficacy endpoint s or the analyses of the secondary 
endpoints.  
All the changes from baseline exploratory endpoints except the HAS and the PGIS/C will 
be analyzed using an ANCOVA model, with explanatory variables being the randomized 
treatment, the stratification factors  and the baseline value. Specifically, for the imputation 
of the 5- item Anorexia Symptom S ubscale, the stratification based on the [ADDRESS_209492] squares (LS) -mean and 95% confidence interval will be presented per 
treatment group together with the LS -mean placebo -corrected treatment effect and its 
95% confidence interval. Statistics will be evaluated in each imputed datasets and pooled using Rubin’s method. 
All the responder  analyses  (CCR and achievement of responder threshold) will be 
analyzed using a logistic regression , with explanatory variables being the randomized 
treatment, and the stratification factors. CCR is a composite measure including both a ≥ 
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 82 of 110 
CONFIDENTIAL   
 
5% body weight gai n from baseline and increase ≥ 2 points in the 5- item Anorexia 
Symptom S ubscale score from baseline in patients who survive until the Visits of the 
analysis. CCR at week 9 was defined as primary efficacy endpoint  in protocol version 3.0 
and previous editions. 
Frequency and rate of responders will be reported with 95% confidence intervals (CIs). 
For the treatment  comparison, the odds ratio will be reported with 95% CIs. Statistics will 
be evaluated in each imputed datasets and pooled using Rubin’s method. 
To explore the correlation between the weight gain and the improvement on the patient -
reported anorexia score, the Pearson’s correlation coefficient will be estimated within 
each treatment group. In addition, a scatter plot of the change from baseline of the  two 
variables will be presented, with a display of the distribution of each single variable. The analysis will be using all available data at each Study Visit. If a sufficient amount of data will be available, relation between numerical endpoints and survival will be explored, as well as relation between changes in weight and anorexia score at other time points. 
 
9.4.6  Safety Analysis  
The safety analysis will be performed on the Safety population. 
Clinical evaluations for safety assessments will include adverse events (AEs) assessment, 
physical examination (PE), vital signs, 12- lead electrocardiogram (ECG), laboratory test 
(hematology, blood chemistry, urinalysis), Tumor assessments, Overall Survival.  
Adverse events, 12- lead ECGs, vital signs, and laboratory ass essments will be 
summarized by [CONTACT_1570]. All safety summaries and analyses will be performed 
based on the Safety Set. All safety and tolerability data will be listed. A treatment-emergent AE is one with an onset date on or after the date of the first dose of the study drug and up to Visit 11 (Day 183 +3 days) the last study visit.  
AEs will be coded using Medical Dictionary for Regulatory Activities (MedDRA) 
dictionary (the version will be provided in the SAP and in the Data Management Plan [DMP]) to  give a preferred term (PT) and a system organ class (SOC) for each event. The 
number and percentage of patients who experienced at least one TEAE, drug- related 
TEAE (defined as AEs with relationship classified by [CONTACT_178308], probably, possibly, unassessable or missing), serious TEAE, serious related, severe 
TEAE (i.e. TEAE with CTCAE grade ≥ 3), AESI (as described below), and the number and percentage of patients withdrawn due to TEAE will be summarized by [CONTACT_2939]. 
For each SOC an d PT, summaries will be made with respect to the proportion of patients 
having at least one occurrence of that event during the study and the total number of 
events. The incidence of TEAEs in each treatment arm will be presented overall, by [CONTACT_3592], and  by [CONTACT_178309][INVESTIGATOR_178239]. Tables of TEAEs will be presented by [CONTACT_8792]. Additional tables including any relationship to study drug will be presented. 
Adverse events of Special Interest are described in Section [IP_ADDRESS]. 
ANAM -17-21  
Final (v5.0 )/[ADDRESS_209493] will be used for “between groups” comparison. All AEs will be listed. 
Physical examination results at screening will be summarized in a frequency table 
(normal/abnormal). Results and relevant findings will be listed.  
Vital signs will be summarized by [CONTACT_178310] (i.e. , last value before first study drug intake). 
Shift tables from baseline to the worst post- baseline results will be provided for the ECG 
overall interpretation. ECG measurements ( HR, QT, QTcF, PR, RR, and QRS) will be 
summarized by [CONTACT_6982]. Outliers’ analysis will be conducted.  
Shift tables from baseline to the Last Value according to NCI CTCAE grade will be 
provided for selected chemistry parameters (ALT, AST, total bilirubin, ALP, creatinine, and glucose) and hematology parameters (hemoglobin, platelet count, white blood cells, neutrophils, and ANC). In addition, a change and % change from baseline will also be 
measured for HbA1c and pre-albumin. 
The best overall tumor responses will be summarized by [CONTACT_178311].  
Overall survival will be described using Kaplan- Meier estimates.  
Individual subject listing for all data will be provided.  
9.4.[ADDRESS_209494] clinically meaningful change was determined 
from a psychometric evaluation using the completed Phase 3 studies (HT -ANAM -301 
and HT- ANAM -302) [ Gelhorn-2016].   
The PGIS and PGIC questionnaires will be administered in this study. Both the PGIS and 
PGIC will consist of a single question each to assess the severity and change in 
appetite/eating -related symptoms (for actual questionnaires, see APPENDIX 6). The 
PGIS is a single -item questionnaire and has a 4 -point Likert -type response scale ranging 
from ‘‘do not have ” symptoms to “ severe” symptoms related to appetite/eating. The 
PGIC is also a single -item questionnaire with a 7 -point Likert -type response scale 
ranging from ‘‘ very much worse’’  to ‘‘very much improved .’’ To note, the terminology of 
“appetite/eating symptoms” is consistent with that used in the cognitive interviews from a qualitative study (Study EVA -[ZIP_CODE]- 00), as it was seen as more easily interpretable by 
[CONTACT_178312] “anorexia symptoms.” The PGIS will be administered at bas eline, Week [ADDRESS_209495] practice for these 
anchors and supported by [CONTACT_143116]- based methods [ Norman-2003;  Revicki -2008]. 
Specifically, the responder definition threshold will be determined as the smal lest 
difference or change in score from baseline that is considered important to the patient 
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 84 of 110 
CONFIDENTIAL   
 
(i.e., those improving on the PGIS and on the PGIC). As such, the difference in scores on 
the PGIS from baseline to Week 6 and Week 9 will be determined, and an im provement 
on the PGIS will be used to define meaningful change based on mean values of the 5-item Anorexia Symptom S ubscale. Similarly, mean values of the 5 -item Anorexia 
Symptom Scale among patients who indicate that their appetite/eating symptoms have improved since starting treatment (based on the PGIC) will be calculated; this value will 
be used to aid in defining a meaningful change in the symptom measure. The results of these anchor -based methods will be supported by [CONTACT_143116]- based methods calculating 
a 0.[ADDRESS_209496] deviation (SD), 0.3 SD, and 0.5 SD, whereby [CONTACT_941] 0.5 SD estimate can be considered to provide an upper boundary for what would constitute a meaningful change, while 0.2 SD provides a lower boundary [ Revicki -2008]. Both anchor -based and 
distribution -based estimates will be plotted together for comparison and triangulation, 
whereby [CONTACT_178313][INVESTIGATOR_178240], and the anchor -based estimates will be assigned more weight than the 
supportive distribution- based methods. A cumulative distribution of response curve for 
the [ADDRESS_209497] of a single question each to assess the level 
of concern about weight and change in worry about  weight (for actual questionnaires, see 
APPENDIX 6). The PGIS is a single -item questionnaire and has a 4- point Likert -type 
response scale ranging from ‘‘I have not had any concerns about my weight ” to “I have 
had severe concerns about my weight ”. The PGIC is also a single- item questionnaire with 
a 7-point Likert -type response scale ranging from ‘‘ very much worse’’  to ‘‘very much 
improved .’’ To note, the terminology of “worry about weight” and “ weight concerns ” is 
consistent with that used in the cognitive interviews from a qualitative study (Study EVA- [ZIP_CODE]-00). The PGIS will be administered at baseline, Week [ADDRESS_209498] practice for these 
anchors and supported by [CONTACT_143116]- based methods [ Norman -2003; Revicki -2008]. 
Specifically, the responder definition threshold will be determined as the smallest difference or change in score from baseline that is considered important to the patient (i.e., those improving on the PGIS and on the PGIC). As such, the difference in scores on 
ANAM -17-21  
Final (v5.0 )/[ADDRESS_209499] improved since starting treatment 
(based on the PGIC ) will be calculated; this value will be used to aid in defining a 
meaningful change in the concerns measure. The results of these anchor -based methods 
will be supported by [CONTACT_143116]- based methods calculating a 0.[ADDRESS_209500] deviation 
(SD), 0.3 SD, and 0.5 SD, whereby [CONTACT_941] 0.5 SD estimate can be considered to provide an upper boundary for what would constitute a meaningful change, while 0.2 SD provides a lower boundary [ Revicki -2008]. Both anchor -based and distribution- based estimates will 
be plotted together for comparison and triangulation, whereby [CONTACT_178313][INVESTIGATOR_178241], and the anchor -based 
estimates will be assigned more weight than the supportive distribution -based methods. A 
cumulative distribution of response curve for the weight change in percentage, one for the treatment group and one for the placebo group, will also be generated to allow a variety of response thresholds to be examined simultaneously and collectively, encompassing all available data.  
9.[ADDRESS_209501] been determined. 
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 86 of 110 
CONFIDENTIAL   
 
10 ETHICAL AND REGULATORY ASPECTS  
10.1 Ethical Considerations  
The study will be performed in accordance with the principles outlined in the Declaration 
of Helsinki [ Helsinki2013] as amended by [CONTACT_178314] 
2013, and the ICH GCP guidelines as well as all local laws and regulations of the countries in which the study is conducted. 
10.1.1  Laws and Regulations  
This clinical study will be conducted in compliance with all international laws and regulations and national laws and regulations of the countries in which the trial is performed, as well as any applicable guidelines.  
10.1.2  Patient’s information sheet and infor med consent form  
All patients invited to participate in the clinical trial are entitled to make their decision 
based on all current available information provided to them by [CONTACT_737]/designee. In addition, they will be given a document in native la nguage written in clear concise lay 
language for review and consideration. The document will previously have been approved by [CONTACT_178315](s) (EC[s]/Institutional Review Boards [IRBs]) and may further be updated as new important information becomes available that may affect subject’s willingness to participate or continue in the trial. This document will tell potentially eligible subjects about the nature of the study drug, its efficacy and safety profile, the route of administratio n, and the human experience 
available. It will also outline the steps of the protocol as they will apply to the individual, including the number of visits and types of procedures/assessments/measurements to be performed so that the individual has a clear pi[INVESTIGATOR_178242], inconveniences and benefits that may accrue from the trial. The patient must be made aware that he/she may refuse to join the trial or may withdraw his/her consent at any time without prejudicing further medical care and that he/she is  covered by [CONTACT_1034]'s indemnity insurance in 
the event of a trial related injury. Contact [CONTACT_178316] -
related injuries will be provided. Patients must also know that their personal medical records may be reviewed in confidence by [CONTACT_1034]'s staff or representatives and by [CONTACT_178317]/EC and that personal information will be collected and retained in a confidential database. Conditions for ensuring the anonymity of data and the security and confiden tiality of the database should be explained. Consent will always be 
given in writing after the patient has had adequate time to review the information and ask questions, if need be. Both the patient and the Investigator or responsible site staff member con ducting the informed consent discussion will personally write the name, sign 
and date the consent form.  
10.1.3  Protocol amendments  
Changes to the protocol may only be made by [CONTACT_3553] a written amendment, which has 
to be approved and signed by [CONTACT_178318] -17-21  
Final (v5.0 )/[ADDRESS_209502] be submitted to the IRB/EC for review and approval unless it covers administrative issues only. In this case, the IRB/EC will be notified of the amendment for information purposes only. 
10.1.[ADDRESS_209503] the safety, rights, and welfare of the subjects.  
In order to obtain interpretable results, neither the Investigator nor the Sponsor/CRO will alter the study conditions agreed upon and set out in this protocol.  
In the event of an isolated, unforeseen instance resulting in a protocol deviation, the 
Investigator is to document this deviation and notify it to the CRO as soon as possible, in writing. In no instance should this increase the subject’s risk or affect the validity of the study data. 
10.1.5  Data collection  
Electronic Case Report Forms (e CRFs) will be used for recording patient’s study data 
using a validated web- based Electronic Data Capture (EDC) system . It is the 
responsibility of the Investigator to ensure that the eCRFs are properly and completely 
filled in. The eCRFs m ust be completed for all patients who have been included in the 
study.  
Each authorized site personnel will be assigned a login and password to enter the EDC 
system  via a secure network . Each login uniquely identifies the user and appropriate 
permissions w ill be set -up according to the user role. The access to the system will be 
granted once the user’s training will be completed and documented.  
Queries will be used to validate/clarify data entered on an eCRF page. Some queries will 
be generated automatical ly by [CONTACT_178319]- defined for the data field. In addition, others will be created manually in the 
system and sent either by [CONTACT_11200] (as result of Source Data Verification) or by [CONTACT_112892].  
Discrepancies raised will be reviewed online to determine the corrective action needed. Changes will be made directly by [CONTACT_172049]. The EDC system’s audit trail will keep track of any information entered, modified and deleted.  The audit trail will include, 
as a minimum, what was entered/changed/modified, who made the action and when the action was made. Any answered query will be reviewed and closed by [CONTACT_55795]. The Investigator will electronically sign the eCRF to validate the content.  
Patient’s source documentation (i.e., hospi[INVESTIGATOR_1332]) will be maintained at the clinic. Source data to be recorded directly onto the eCRFs will be communicated in advance. In cases where source documents are not eCRFs, the information on  the eCRFs must match 
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 88 of 110 
CONFIDENTIAL   
 
the source documents. Source data verification will be regularly performed by [CONTACT_178320].  
All the study questionnaires will be filled on electronic diary at the timepoints mentioned 
in the study flow chart . Data from study questionnaires will be then automatically 
transferred  to EDC .  
10.1.6  Monitoring and Quality Assurance  
The study will be monitored by [INVESTIGATOR_30909]’s adequately qualified and trained clinical monitors on a regular basis throughout the study period to ensure the proper conduct of the clinical trial. The purposes of clinical trial monitoring are to verify that the rights and well -being 
of study patients are protected, that the reported trial data are accurate, complete and verifiable against the source documents, and that the study is conducted in accordance with the current protocol, Good Clinical Practice guideline and applicable regulatory requirements. During the monitoring visits, monitors will verify the  following including, 
but not limited to , patient informe d consent, patient’s eligibility, safety data and 
reporting, quality of source documents and eCRF data against patient’s medical records. If inconsistencies are identified, the corresponding corrections to the eCRF data will have to be made by [CONTACT_737]. Monitors will also check patient compliance, accrual, drug handling, including dispensing procedures and accountability logs, delegation of responsibilities within the Investigator’s team, relevant communications with family doctors, if any, ancillary equipment and facilities, including refrigerators and freezers, local labs, etc. The Investigator and other site staff involved in the study must allocate enough time to the monitor at these visits. 
Upon request by [CONTACT_1034], or following the CRO’s audit plan, on- site study audits 
may be conducted in order to ensure the study is in compliance with GCP, applicable 
regulatory requirements, and the study protocol. The auditing activities may also be conducted after study completion. 
In addition, Regulatory Authorities may wish to conduct on- site inspections (during the 
study or after its completion). If a Regulatory Authority notifies the Investigator of an 
inspection or visits the site unannounced for purposes of conducting an inspection, the Investigator must inform the study Sponsor and CRO immediately. The Investigator will 
make all efforts to facilitate the conduct of the audits and inspections giving access to all necessary facilities, data and documents.  
10.1.7  Study Documentation and Records retention 
The m edical (hospi[INVESTIGATOR_307]) files of trial patients should be retained in accordance with 
national legislation (and in accordance with the maximum period of time permitted by [CONTACT_5035][INVESTIGATOR_307] (or institution/private practice).  
The Sponsor should ensure that it is specified in the protocol or other written agreement that the investigator(s)/institution(s) will permit trial- related monitoring, audits, IRB/EC 
review, and regulatory inspection(s), providing direct access to source data/documents. All the essential study docu ments should be retained at the sites for the period required 
by [CONTACT_178321], or for a period of at least fifteen (15) years 
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 89 of 110 
CONFIDENTIAL   
 
following the completion or discontinuation of the s tudy, whichever is longer  and in any 
case in accordance with FDA regulation 21 CFR 312.62(b) and (c) and ICH -GCP 
guidelines [ Reilly2013]. Should the Investigator wish to assign the study documentation 
to another party or move to another location, the Sponsor should promptly be notified. 
10.1.[ADDRESS_209504] 
parties any confidential information disclosed or provided by [CONTACT_178322]- related products. The Investigator agrees to use such 
information only to accomplish the present study tasks and not to use it for any other purposes without the prior written consent by [CONTACT_1034]. Prior to the study start -up, 
each Institution/Investigator as well as each subcontractor to be involved in the study should sign a confidentiality agreement with the CRO on behalf of the Sponsor. 
10.1.9  Publication policy  
Helsinn Healthcare SA is committed to public disclosure of research re sults that involve 
Helsinn products and for Helsinn sponsored publications, the International Committee if 
Medical Journal Editors (ICMJE) will apply to all named authors. As a general rule, the Sponsor and the Investigator(s) agree that no publications presenting or discussing data and/or results from clinical trials sponsored by [CONTACT_178323](s) has/have completed the study, the data have been interpreted, and the final report has been issued. As a rule, the Sponsor is free to use the data collected in the sponsored study for the drug registration, world- wide scientific 
product documentation, and for publication. 
The Sponsor shall have the sole and exclusive right to the first publication of the study 
data. Such Sponsor publication is intended to be a multi -center publication of the study 
data, collected from all investigators and institutions participating in the study. If the Investigator is interested in contributing to or participating in the Multi- Center 
Publication, he or she must contact [CONTACT_1034]. Selection of authors/participants will be governed by [CONTACT_1034], considering individuals’ contribution to the Study. 
The Institution and the Investigator may publish or otherwise present the results of the 
Study Data obtained by [CONTACT_178324]/or the Investigator  provided that all of the following conditions have been satisfied: (i) the Multi -Center Publication has occurred; 
or, if no such publication has occurred, a manuscript should be submitted within 12 months of Study Drugs’ first approval or within 18 months of the decision to discontinue  Study Drugs’ development, allowing for congress presentation first; (ii) before submitting the Independent Submission to a publisher, reviewer or other outside party, the Institution and/or the Investigator must submit the proposed Independent Submission to the Sponsor and allow the Sponsor at least sixty (60) days to review and provide comments; (iii) the Institution and/or the Investigator shall, as requested by [CONTACT_1034], delete all references to Confidential Information (excepting the results of the Study obtained by [CONTACT_178325]); (iv) the Institution and the Investigator shall consider the Sponsor’s comments and proposed revisions in good faith; and (v) if at any point during the initial sixty (60) day review the Sponsor so requests, the Institution 
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 90 of 110 
CONFIDENTIAL   
 
and/or the Investigator shall delay the publication or presentation of the Independent 
Submission for up to sixty (60) additional days in order to permit the Sponsor time to obtain Intellectual Property protections. 
10.1.10  Insurance  
The Sponsor/designee will obtain clinical study liability insurance, which covers health 
impairments resulting from drugs and/or substances/investigational products administered in the course of this study for which the patient has given his/her written informed consent.  
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 91 of 110 
CONFIDENTIAL   
 
11 REFERENCES 
Allison DB, Casey DE. Antipsychotic induced weight gain: a review of the literature. J 
Clin Psychiatry 2001; 62: Suppl 7: 22-31. 
Andreyev HJ, Norman AR, Oates J, Cunningham D. Why do patients with weight loss 
have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer. 1998 Mar;34(4):503-9. 
Aoyagi T, Terracina KP, Raza A, Matsubara H, Takabe K. Cancer cachexia, mechanism 
and treatment. World Journal of Gastrointestinal Oncology. 2015;7(4):17-29. doi:10.4251/wjgo.v7.i4.17. 
Common Terminology Criteria for Adverse Events (CTCAE) (Terminology Criteria for 
Adverse Events (CTCAE, Version Version 5.0 Published: 27 Nov 2017).  
Currow DC, Abernethy AP. Anamorelin hydrochloride in the treatment of cancer 
anorexia-cachexia syndrome. Future oncology. 2014 Apr;10(5):789-802. 
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, 
Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. 
FACIT.org: Functional Assessment  of Chronic Illness Therapy; 
http://www.facit.org/FACITOrg. Accessed on 28 Jun 2017. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and 
classification of cancer cachexia: an international consensus. Lancet Oncol. 2011May;12(5):489-95. 
Fielding R, Wong WS. Quality of life as a predictor of cancer survival among Chinese 
liver and lung cancer patients. Eur J Cancer. 2007; 43:1723-1730. 
Gelhorn, H. Psychometric Properties of the FAACT Additional Concerns Subscale 
(A/CS) fo r Measurement of Anorexia in Patients with Non- Small Cell Lung Cancer. 
Qual Life Res 2016; 24:71. 
Guillory B, Splenser A, Garcia J. The role of ghrelin in anorexia -cachexia syndromes. 
Vitam Horm. 2013;92:61-106. Hinsley R, Hughes R. The reflections you get: an exploration of body image and 
cachexia. Int J Palliat Nurs. 2007;13:84–89. 
Hopkinson J. Nutritional support of the elderly cancer patient: the role of the nurse. 
Nutrition. 2015; Apr;31(4). 
ANAM -17-21  
Final (v5.0 )/[ADDRESS_209505] of cancer cachexia. J Cache xia Sarcopenia Muscle. 
2014;5:89-94.  
International Conference on Harmonization of Technical Requirements for Registration 
of Pharmaceuticals for Human Use. ICH – Efficacy Topic 6(R1): Guideline for Good 
Clinical Practice, Step 4, 10 Jun 1996 and Step 5, Jul 2002. 
International Conference on Harmonization of Technical Requirements for Registration 
of Pharmaceuticals for Human Use. ICH – Efficacy Topic E2A: Clinical Safety Data 
Management: Definition and Standards for Expedite reporting, [ADDRESS_209506] 1994 
Internat ional Conference on Harmonization of Technical Requirements for Registration 
of Pharmaceuticals for Human Use. ICH – Efficacy Topic 9: Guidance on Statistical 
Principles for Clinical Trials, 5 Feb 1998. 
Investigator’s Brochure Anamorelin; Edition Jan 2022. 
Kojima  M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a 
growth hormone- releasing acylated peptide from stomach. Nature. 1999 Dec 
9;402(6762):656-60. 
Kumar NB, Kazi A, Smith T, Crocker T, Yu D, Reich RR, et al. Cancer cachexia: 
traditional thera pi[INVESTIGATOR_178243] -based approaches to treatment. Curr 
Treat Options Oncol. 2010 Dec;11(3-4):107-17. Lis CG, Gupta D, Grutsch JF. Can anorexia predict patient satisfaction with quality of 
life in advanced cancer? Support Care Cancer. 2009; 17: 129–35.  
McGrath P. Reflections on nutritional issues associated with cancer therapy. Cancer 
Pract. Mar -Apr 2002;10(2):94-101.  
McKernan M, Mcmillan Dc, Anderson JR, Angerson WJ, Stuart RC. The relationship between quality of life (EORT QLQ -C30) and survival in patients with gastro -
oesophageal cancer. Br J Cancer. 2008; 98:888-893. 
Molfino A, Muscaritoli M, Rossi Fanelli F. Anorexia assessment in patients with cancer: 
a crucial issue to improve the outcome. J Clin Oncol. 2015 May 1;33(13):1513. 
Montazer i A. Quality of life data as prognostic indicators of survival in cancer patients: 
an overview of the literature from 1982 to 2008. Health Qual Life Outcomes. 2009;7:102. 
Navari RM et al. Olanzapi[INVESTIGATOR_178244]- Induced Nausea and 
Vom iting. N Engl J Med 2016;375:134-42. 
NCCN guidelines on antiemesis version 2.2020, 
https://www.nccn.org/professionals/physician_gls/pdf/antiemesis  
ANAM -17-21  
Final (v5.0 )/[ADDRESS_209507] Deviation. Medical Care. 
May, 2003. 41 (5) 582-592. 
Oberholzer R, Hopkinson JB, Baumann K, Omlin A, Kaasa S, Fearon KC, Strasser F. 
Psychosocial effects of cancer cachexia: a systematic literature search and qualitative analys is. J Pain Symptom Manage. 2013;46:77–95.  
Patel JD, Pereira JR, Chen J, Liu J, Guba SC, John WJ, et al. Weight gain as a prognostic 
factor on patient outcomes in advanced, nonsquamous, non- small cell lung cancer 
[abstract]. J Thorac Oncol. 2013 Nov;[ADDRESS_209508] 2:S578-9. Abstract no. P1.10-034. 
Ratitch B. Multiple Imputations. In: O'Kelly M and Ratitch B, editors. Clinical Trial with 
Missing Data: A Guide for Practitioners. West Sussex: John Wiley & Sons Ltd, 2014. p 185-256. 
Ratitch B, Lipkovic I, and O'Kelly M. Combining Analysis Results from Multiply 
Imputed Categorical Data. PharmaSUG [ADDRESS_209509], Cella D, Sloan J. Recommended methods for determining 
responsiveness and minimally important differences for patient -reported outcomes. J Clin 
Epi[INVESTIGATOR_5541]. Feb 2008; 61:102-109. 
Ribaudo JM, Cella D, Hahn EA, et al. Re -validation and shortening of the Functional 
Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire. Qual Life Res. 
2001;9:1137-1146. 
Rodriguez AM, Braverman J, Aggarwal D, Friend J, Duus E. The experience of weight 
loss and its associated burden in patients with non- small cell lung cancer: results of an 
online survey. Journal of Cachexia, Sarcopenia and Muscle - Clinical Reports. 2017; 
Volume [ADDRESS_209510] a worse outcome when undergoing chemotherapy for lung cancers? Br J 
Cancer. 2004 May;90:1905-11.  
Sullivan P, Nelson JB, Mulani PM, Sleep D. Quality of life as pote ntial predictor 
morbidity and mortality in patients with metastastic hormone -refractory prostate cancer. 
Qual Life Res. 2006; 15:1297-1306. Sundstrøm S, Bremnes RM, Brunsvig P, Aasebø U, Kaasa S, Norwegian Lung Cancer 
Study Group. Palliative thoracic radiotherapy in locally advanced non- small cell lung 
cancer: can quality -of life assessments help in selection of patients for short - or long-
course radiotherapy? J Thorac Oncol. 2006; 1:816-824. 
Temel JS, Abernethy AP, Currow DC, Friend J, Duus EM, Yan Y, Fearon KC. 
Anamorelin in patients with non- small- cell lung cancer and cachexia (ROMANA 1 and 
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 94 of 110 
CONFIDENTIAL   
 
ROMANA 2): results from two randomised, double -blind, phase 3 trials. Lancet Oncol. 
2016 Apr;17(4):519-31.  
Trudel L, Tomasetto C, Rio MC, Bouin M, Plourde V, Eberling P, Poitras P. 
Ghrelin/motilin -related peptide is a potent prokinetic to reverse gastric postoperative ileus 
in rat. Am J Physiol Gastrointest Liver Physiol. 2002 Jun;282(6):G948-52. 
von Haehling S, Anker SD. Cachexia as a major underestimate d and unmet medical need: 
facts and numbers. J Cachexia Sarcopenia Muscle. 2010 Sep;1(1):1-5.  WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving 
Human Subjects. 64th WMA General Assembly, Brazil, Fortaleza, Oct 2013. Yap YG. Drug induced QT prolongation and torsades de pointes . Camm AJ Heart 2003; 
89:1336-1372 Yavuzsen T, Davis MP, Walsh D, LeGrand S, Lagman R. Systematic review of the 
treatment of cancer -associated anorexia and weight loss. J Clin Oncol. 2005;23:8500–
8511. 
Yeo W, Mo FK, Koh J, Chan AT, Leung T, Hui P, et al. Quality of life is predictive of 
survival in patients with unresectable hepatocellular carcinoma. Ann Oncol. 2006; 
17:1083-1089. 
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 95 of 110 
CONFIDENTIAL   
 
12 APPENDICES 
APPENDIX 1 : EASTERN COOPERATIVE ONCOLOGY GROUP 
PERFORMANCE SCALE  
APPENDIX 2 : BODY WEIGHT MEASUREMENTS -STUDY SPECIFIC 
PROCEDURES  
APPENDIX 3 : CYP3A4 INHIBITORS AND INDUCERS  
APPENDIX 4 : FACIT MEASUREMENTS  
APPENDIX 5 : S CORING G UIDELINES   
APPEN DIX 6 : PATIENT GLOBAL IMPRESSION OF SEVERITY (PGIS) AND PATIENT GLOBAL IMPRESSION OF CHANGE (PGIC)  
APPENDIX 7 : HUNGER ASSESSMENT SCALE  
APPENDIX 8 : NEW YORK HEART ASSOCIATION (NYHA) CLASSIFICATION  
  
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 96 of 110 
CONFIDENTIAL   
 
APPENDIX 1:  EASTERN COOPERATIVE ONCOLOGY GROUP 
PERFORMANCE SCALE  
ECOG Performance Status (To be rated by [CONTACT_10670]) 
Score  Description  
0 Fully active, able to carry on all pre- disease performance without restriction  
1 Restricted in physically strenuous activity but ambulatory and able to carry out 
 Work of a light or sedentary nature (e.g., light house work, office work) 
2 Ambulatory and capable of all selfcare but unable to carry out any work activities.  
Up and about more than 50% of waking hours 
3 Capable of only limited selfcare, confined to bed or chair more than 50% of 
waking hours 
4 Completely disabled.  Cannot carry on any selfcare.  Totally confined to bed or 
chair  
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 97 of 110 
CONFIDENTIAL   
 
APPENDIX 2:  BODY WEIGHT MEASUREMENTS -STUDY 
SPECIFIC PROCEDURES  
Sites will be instructed to follow: 
• Patient weighing for this study (Visit 1 to Visit 10) may only be performed by a 
Sponsor- trained and certified healthcare professional  
• Body weight should be measured at each visit 
• Calibrated scale dedicated for use in this study will be used every visit for the study, including for screening visits. Sponsor will make sure the same scale is used at each site.  
• Scales will be used on hard flooring, such as tile, wood, or cement for accuracy 
• Sites will be instructed to weigh the participants at approximately the same time of the day every visit, on empty stomach (in mornings before breakfast) 
• Study participants will be instructed to void before getting on weighing scale 
• Study participants will be instructed to remove shoes and clothing for accurate weight measurement. Patients will be weighed wearing only a hospi[INVESTIGATOR_178245], if desired, underwear only 
  
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 98 of 110 
CONFIDENTIAL   
 
APPENDIX 3:  CYP3A4 INHIBITORS AND INDUCERS  
CYP3A4 Inhibitors  
Strong CYP3A4 Inhibitors  
ketoconazole 
clarithromycin  
itraconazole  
nefazodone telithromycin  
Moderate CYP3A4 Inhibitors  
aprepi[INVESTIGATOR_178246]3A4 Inhibitors  
cimetidine  
 
CYP3A4 Inducers  
efavirenz  
nevirapi[INVESTIGATOR_178247]2 phenytoin2 pi[INVESTIGATOR_178248]1  
St. John's Wort 
troglitazone  
Refer to the following website for a complete list: 
http://medicine.iupui.edu/flockhart/table.htm  
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 99 of 110 
CONFIDENTIAL   
 
APPENDIX 4:  FACIT MEASUREMENTS 
The FACIT Measurement System is a collection of QOL questionnaires targeted to the 
management of chronic illness : “FACIT” (Functional Assessment of Chronic Illness 
Therapy).  FACIT is a broader, more encompassing term that includes the FACT questionnaires. The FACT -G is a 27 -item compi[INVESTIGATOR_178249]: Physical Well -Being , Social/Family Well- Being, Emotional Well -
Being, and Functional Well -Being. For this study we plan to administer all four domains. 
The FAACT A/CS domain is a 12- item measure of patients’ perceptions of 
anorexia/cachexia symptoms and concerns . The FACIT -F domain is a 13 -item measure 
specifically to address the physical and functional consequences of fatigue [FACIT.org]. 
FACIT questionnaires are all formatted for self -administration, and use a 5- point Likert -
type scale where patients rate each item from 0 to  4 (0 = Not at all; 1 = A little bit; 2 = 
Somewhat; 3 = Quite a bit; and 4 = Very Much); the recall period for each question is 
“during the past 7 days”.   
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 100 of 110 
CONFIDENTIAL   
 
 
 

ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 101 of 110 
CONFIDENTIAL   
 
 

ANAM -17-21  
Final (v5.0 )/[ADDRESS_209511] 9 
 

ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 103 of 110 
CONFIDENTIAL   
 
 
 

ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 104 of 110 
CONFIDENTIAL   
 
APPENDIX 5:  SCORING GUIDELINES  
 
 
 

ANAM -17-21  
Final (v5.0 )/[ADDRESS_209512] ACS, the following 
scores will be computed: - 5- item Anorexia Symptom S ubscale = C6+(4 -ACT3)+(4 -ACT6)+(4 -ACT7)+(4 -
ACT10)  - 4-item Anorexia Concerns Subs cale = ACT1+(4 -ACT2)+(4 -ACT4)+(4 -ACT9)  

ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 106 of 110 
CONFIDENTIAL   
 
 
Additionally, based on the here -above Fatigue Subscale (FACIT -F), the Physical well -
being and the Functional well-being, the FACIT -F TOI will be computed as: 
FACIT -F TOI = FACIT -F + PWB + FWB.  

ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 107 of 110 
CONFIDENTIAL   
 
APPENDIX 6:  PATIENT GLOBAL IMPRESSION OF SEVERITY 
(PGIS) AND PATIENT GLOBAL IMPRESSION OF CHANGE (PGIC)  
 
Patient Global Impression of Severity (PGIS)  
Which of the following statements be st describes your current appetite/eating -related 
symptoms?  (Please pi[INVESTIGATOR_178250])  
 I currently do not have any appetite/eating-related symptoms  
 I currently have minor appetite/eating- related symptoms  
 I currently have moderate appetite/eating -related symptoms  
 I currently have severe appetite/eating -related symptoms  
 
Please choose the response below that best describes your current concerns about your 
weight. ( Please pi[INVESTIGATOR_178250] ) 
 I have not had any concerns about my weight 
 I have had minor concerns about my weight 
 I have had moderate concerns about my weight 
 I have had severe concerns about my weight 
 
  
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 108 of 110 
CONFIDENTIAL   
 
Patient Global Impression of Change (PGIC)  
Since the start of the treatment, how would you describe your change in appetite/eating-
related symptoms? ( Please pi[INVESTIGATOR_178250] ) 
 Very much improved   
 Much improved  
 Minimally improved   
 No change    
 Minimally worse   
 Much worse   
 Very much worse  
 
Since the start of treatment, how would you describe the change in how much you worry about your weight?  ( Please pi[INVESTIGATOR_178250] ) 
 
 Very much improved   
 Much improved  
 Minimally improved   
 No change    
 Minimally worse   
 Much worse 
 Very much worse 
 
Since the start of the treatment, how would you describe your change in overall 
condition? (Please pi[INVESTIGATOR_178250]) 
 Very much improved   
 Much improved  
 Minimally improved   
 No change    
 Minimally worse   
 Much worse 
 Very much worse 
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 109 of 110 
CONFIDENTIAL   
 
APPENDIX 7:  HUNGER ASSESSMENT SCALE  
 
Please circle or mark one number per line to indicate your response as it applies to the 
pas
t [ADDRESS_209513] felt hungry.  
 
  
 
  
My family and friends are 
pleased with my appetite.  
 
 
 
    
 
  Not at all  A little bit  Somewhat  Quite a bit  Very much  
0 1 2 3 4 
Not at all  A little bit  Somewhat  Quite a bit  Very much  
0 1 2 3 4 
 
    
 
 
 
ANAM -17-21  
Final (v5.0 )/13 Jul  2022   Clinical Study  Protocol   Helsinn Healthcare SA  
  
 
Page 110 of 110 
CONFIDENTIAL   
 
2  2 APPENDIX 8:  NEW YORK HEART ASSOCIATION (NYHA) 
CLASSIFICATION 
 NYHA grading  MET*  
Class I  No limitations. Ordinary physical activity does not cause 
undue fatigue, dyspnoea or palpi[INVESTIGATOR_814] (asymptomatic LV dysfunction).  >7 
Class II  Slight limitation of physical activity. Ordinary physical 
activity results in fatigue, palpi[INVESTIGATOR_332], dyspnoea or angina pectoris (mild CHF).  5 
Class III  Marked limitation of physical activity. Less than ordinary physical activity leads to symptoms (moderate CHF).  2–[ADDRESS_209514] (severe CHF).  1.6 
*MET (metabolic equivalent) is defined as the resting VO for a 40- year-old 70kg man.1 MET = 3.5mL O 
/min/kg body weight.  
Reproduced from: National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand (Chronic Heart Failure Guidelines  
Expert Writing Panel). Guidelines for the prevention, detection and management of chronic he art failure in 
Australia. Updated Oct 2011  